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Part I describes the design and efforts toward the total synthesis of novel 
analogs of 4-demethoxydaunorubicin. The design of the analogs (24 and 
25) was based on the ability of these compounds to intercalate into DNA 
demonstrated by computer graphics studies. The synthesis of the 9a-homo 
analog started from known 1,4-dimethoxy-2,3-dimethylbenzene. Friedel-
Crafts acylation of 27 with phthalic anhydride afforded 28 in 76% yield. 
Introduction of the benzylic hydroxy! group at carbon 7 of 32 failed during 
the hydrolysis step. Standard and/or alternative hydrolysis procedures gave 
dehydration product 50, decomposition or starting material. 
1,2-Keto transposition of 26 gave ketone 38, which gave us an entry 
into the synthesis of the 8a-homo analog. Standard transposition 
procedures proved to be more difficult than anticipated. The transformation, 
however, was accomplished in six steps in 43% yield. A direct route for 
analog 25 started from 1,4-dihydronaphthalene derivative 39. A ring 
expansion reaction performed on tetralone 42 gave 38 in 75% yield. 
Friedel-Crafts acylation of 44 gave 45 in 85% yield. Functionalization of the 
benzylic position of compound 48 failed during the bromination step. 
The syntheses of analogs 24 and 25 could not be finished due to the 
intractable behavior of some of the intermediates. 
Part II describes the elucidation of the biosynthesis of coloradocin by the 
use of stable isotopes. The major carbon chain is polyketide and derived 
from acetate-propionate and methionine as shown by feeding experiments 
with [1-13C]-, [2-13C]-, [1,2-13C]-acetate, [1-13CJ-propionate and L-[methyl-
13C]-methionine. 
The bioorigin of the minor carbon chain was examined using the above 
mentioned isotopes as well as with -13C]-glutamate, [2,3-13C]-succinate, 
[3-13C]-oxaloacetate and [UeJ-glucose. Based on the results, the chain is not 
a polyketide and its bioorigin remains to be elucidated. 
Part III describes the total synthesis of the antimicrobial agent amorfrutin 
A. The synthesis was accomplished in 12 steps from known 3,5-dimethoxy-
benzaldehyde in 11% yield. The synthetic route employed was efficient, 
apparently flexible, and regiospecific for 2-carboxylated bibenzyls and 
related molecules. 
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Parti 
Studies Directed Toward the Total Synthesis of 
4-Demethoxy-A-Homodaunorubicin Analogs 
A. Introduction 
Although surgery is the primary method for treatment of solid tumors, 
and radiation is used for skin cancer and deeper localized tumors, the 
effective treatment of occult micrometastases not accessible to surgery or 
localized radiotherapy requires chemotherapy. It is clear that the most 
effective role of chemotherapeutic agents against solid tumors is as an 
adjuvant to these initial modes of therapy. 
1. Anthracycline Antibiotics: Classification, Isolation, and 
Biological Properties of Doxorubicin and Daunorubicin. 
The anthracyclines, including doxorubicin (1, adriamycin) and 
daunorubicin (2, daunomycin), are a large and important family of antitumor 
antibiotics. Within this class, doxorubicin is the leading drug in present 
cancer chemotherapy. 
The anthracyclines are divided into two classes, in accordance with the 
selective effects on the inhibition of nucleic acid synthesis: Type I 
anthracyclines, exemplified by doxorubicin and carminomycin (Figure 1), 
inhibit DNA, whole cell RNA, and nucleolar RNA synthesis at comparable 
concentrations. Type II anthracyclines, exemplified by aclacinomycin and 
marcellomycin (Figure 2), inhibit whole cellular RNA synthesis and nucleolar 
preribosomal synthesis at six- or seven-fold lower and at 170-1250-fold 
lower concentrations, respectively, than those required for the inhibition of 
DNA synthesis.1 
1 
Type-l Anthracyclines 
Doxorubicin: R - C H 3 , X • OH (1, Adriamycin) 
Daunorubicin: R = CH 3 , X = H (2, Daunomycin) 
Carminomycin: R - H, X • H 
Figure 1 
Type-l l Anthracyclines 
Figure 2 
2 
Daunorubicin was isolated in 1963 from Streptomyces peucetius by 
Farmitalia in Italy,2 and independently at Rhdne-Poulenc in France3 from S. 
coeruleorubidis. Six years later, doxorubicin was isolated from a mutant 
strain of S. peucetius by the Farmitalia group.4 
In vivo and in vitro studies5'8 of these two compounds showed significant 
inhibition of different experimental tumors such as Erlich carcinoma, L1210 
leukemia, and sarcoma 180. Doxorubicin was superior to daunorubicin in 
most of these cases. 
After clinical trials, daunorubicin was one of the first succesful and 
efective drugs for the treatment of acute leukemia.9 Doxorubicin, on the other 
hand, became the leading drug in cancer chemotherapy, as a result of its 
broad spectrum against solid tumors and malignant lymphomas.8*10 
Unfortunately, these agents exhibit undesired side effects, such as 
stomatitis, alopecia, myelodepression, and gastrointestinal disturbances. 
However, the most serious dose-limiting side effect is the development of 
cumulative dose-dependent cardiotoxicity.10 The clinical importance of these 
agents, together with the serious side effects, have provided a powerful 
stimulus to the search for better analogs. 
2. Mechanism of Action. 
Several mechanistic pathways have been proposed for the 
antineoplastic activity of these agents, including: 
a) inhibition of DNA and RNA biosynthesis by intercalation into the DNA 
double helix 
b) alkylation of macromolecules by bioreductive activation 
3 
c) generation of highly active superoxides by bioreductive activation 
d) interaction with topoisomerase ll/DNA complexes 
e) cell membrane surface interaction. 
Each mechanistic pathway will be discussed later in this section, 
a. Inhibition of DNA and RNA Biosynthesis bv Intercalation into the DNA 
Double Helix. 
The effects of daunorubicin and doxorubicin on DNA synthesis have 
been studied in detail. It was found that DNA polymerase a, the putative 
replicative polymerase, was inhibited in preference to DNA polymerase p\ 
the repair polymerase.11 Furthermore, the observation that daunorubicin was 
more lethal to cells in the late S-phase, than in G i or G2, prompted the 
suggestion that the drug can find access to double stranded helical DNA 
during the replication process.1 2 Matsuzawa and co-workers,13 using 92 
anthracyclines, showed a correlation between cytotoxicity and inhibition of 
nucleic acid synthesis. Studies which show the correlation between the 
degree of inhibition of DNA polymerases and the ability of the drugs to bind 
to DNA, demonstrated that the inhibition was a direct consequence of DNA 
binding.14*16 Stutter and co-workers17 showed that the formation constant of 
the daunorubicin- and doxorubicin-DNA complexes were approximately 7 x 
10s and 2 x 108 M"1, respectively. These studies as well as the elevation of 
DNA melting temperatures indicated that intercalation is the mechanism by 
which daunorubicin and related anthracyclines inhibit nucleic acid 
biosynthesis. Spectroscopic studies on daunorubicin, such as hypsochromic 
and bathochromic changes in the visible spectrum, as well as physical 
characteristics including increased viscosity and decreased buoyant density 
4 
of DNA, 1 8 uncoiling of supercoiled closed circular DNA, 1 9 and changes in the 
fluorescence emission spectrum,20 showed that this drug satisfied the criteria 
for an intercalating agent. 
Analysis of NMR data of aromatic and alicyclic protons of daunorubicin 
followed by complexation with different deoxydinucleotides indicated 
differences in affinity and suggested that ring A was in the half-chair 
conformation with the acetyl side chain equatorially oriented, both in solution 
and in the complexes (Figure 3). 2 1 The analysis also suggested that there 
were intermolecular hydrogen-bonds between the axial 9-OH with either 
water molecules or the phosphate anion at the intercalation site.2 1 Downfield 
shifts and line broadening of DNA 3 1 P signals suggested unwinding of the 
DNA double helix as a consequence of daunorubicin intercalation.22 
Solution and Solid State Conformation off Daunorubicin 
Figure 3 
All of these suggestions were corroborated when Quigley and 
co-workers2 3 solved the crystal structure of daunorubicin-d(CpGpTpApCpG) 
complex by X-ray diffraction analysis at 1.54A resolution. Several years 
5 
later, this group reported another molecular structure of this complex at 1.2k 
resolution, where the six base pair fragment of double-helical DNA had two 
molecules of daunorubicin, 166 water molecules, and two sodium ions 
bound to i t . 2 4 These studies allowed the researchers to identify three 
principal functional components of the anthracycline antibiotics: a) the 
intercalator portion (rings B-D), b) the anchoring functions associated with 
ring A, and c) the amino sugar. 
The aglycone chromophore of daunorubicin intercalates at the CpG 
sequences of the d(CGTACG) duplex by skewering the double helix, and is 
oriented at right angles to the long dimension of the DNA base pairs 
(Figures 4a and 4b). Ring D protrudes out along the major groove and ring 
A, along the minor groove. The methoxy group of ring D, found within the 
major groove, participates in the coordination with the sodium ion, and this 
coordination provides some stability for the complex. Substituents on ring A 
have hydrogen-bonding interactions with the base pairs above and below 
the intercalation site. 
The functional groups at C-9 seem to anchor the molecule into the DNA, 
by stabilizing the complex via three hydrogen bonds. The 0-9 hydroxyl 
group forms two hydrogen bonds with a guanine residue adjacent to the 
chromophore, donating one to N-3 and receiving one from N-2. The other 
hydrogen-bonding interaction is seen on the other side of the aglycone ring, 
which involves the C-13 carbonyl oxygen. This carbonyl oxygen is within 
hydrogen-bonding distance to a bridging water molecule, which itself is 
hydrogen-bonded to carbonyl 0-2 of the cytosine ring C-1 in the base pair 
above the intercalator. 
6 
X-Ray Crystal Structure of 
Daunorublcln-d(CGTACG) Complex 
• 
Crystal structure of daunorubicin intercalated into the d-(CGTACG) 
hexamer viewed perpendicular to the 2-fold axis. The + marks 
represent water molecules. 
7 
Figure 4a 
Diagram of Daunorubicin Intercalated Into the 
d - (CGTACG) Hexamer 
Figure 4b shows a diagram of daunorubicin (D14) intercalated into 
the DNA hexamer. Four base pairs of the hexamer are shown. 
Hydrogen bonds in the base pairs are represented by dashed 
lines. There are two bridging waters (W1 and W2) that form 
hydrogen bonds between 013 of daunorubicin and 02 of C1 and 
between N3' of daunorubicin and N3 of A4, respectively. A sodium 
ion is found to coordinate to N7 of G12, 04 and 05 of 
daunorubicin, and to three water molecules to form a distorted 
octahedral arrangement in the major groove. 
8 
Figure 4b 
The amino group on the amino sugar ring has been implicated in 
electrostatic interactions between daunorubicin and the phosphate group of 
the nucleic acid; 2 5 however, direct interactions are not observed in this 
complex. The sugar N-3' atom is strongly hydrogen-bonded to two water 
molecules and possibly to the 0-2 of residue C-5 (C-11). 
Another important interaction in the major groove involves a hydrated 
sodium ion, which is coordinated to the N-7 position of G-12 and the 0-4 and 
0-5 of daunorubicin in a distorted octahedral geometry. 
The intercalation model described above indicates that the antitumor 
properties exhibited by most of the active anthracyclines is proportional to 
the extent of its binding to ONA. However, N-trifluoroacetyl-doxorubidn-14-
valerate (3), 2 6 N,N-dibenzyldaunorubicin (4), 2 7and carminomycin-11 -methyl 
ether (5), 2 8 shown in Figure 5, have impressive antitumor activity in mice, but 
little or no affinity for DNA. These results suggest that intercalation might not 
be the only mechanism for expression of antineoplastic activity of the 
anthracyclines. 
b. Alkvlation of Macromolecules by Bioreductive Activation 
(Two-electron Reduction Process). 
Anaerobic reduction of daunorubicin and doxorubicin in microsomes by 
NADPH and in solution by dithionite gives 7-deoxydaunomycinone (6) and 
7-deoxyadriamycinone (7), respectively2 9"3 2 and/or covalent binding of the 
drugs to biological macromolecules.33*35 On the basis of these findings, 
Moore and co-workers 3 6 , 3 7 proposed a bioreductive activation mechanism 
by which these drugs are activated by reductive elimination of the sugar. 
9 
N-TrlfluoroacetyIdoxorubIcln-14-valerate (3), N.N-dlbenzyldaunorublcIn (4), 
and carmlnomycln-11-methyl ether (5) 
Koch and Kleyer 3 8 demonstrated that anaerobic reduction of 
daunorubicin with the reducing agent 3,5,5-trimethyl-2-oxo-morpholin-3-yl 
(8) yields the deoxyaglycone 6 via two sequential one-electron reduction 
steps to give the hydroquinone 9, which rapidly eliminates daunosamine to 
give quinone methide 1 0 . Protonation of 10 leads to 
7-deoxydaunomycinone (Figure 6). Tautomer 10 was characterized via 
UV-visible spectroscopy and is proposed as the biologically active form of 
daunorubicin which reacts with nucleophilic sites in DNA or other 
macromolecules. 
Examination of the structure of quinone methide 10 as a possible 
intermediate, which could lead to covalent binding to biological 
macromolecules, reveals two possible pathways. In the first pathway, the 7 
position of 10 serves as an electrophilic site for reaction with nucleophilic 
sites in the macromolecules. In the second pathway, the 7 position serves as 
a nucleophilic site for reaction with electrophilic sites in the macromolecules. 
The reactivity of the quinone methide intermediate as an electrophile 
has been investigated by Fisher and co-workers. 3 9* 4 0 They demonstrated 
that the quinone methide intermediate can undergo nucleophilic trapping 
with thiol and thiolate groups such as ethyl xanthate and N-acetylcysteine. In 
the nucleophilic trapping experiment of the quinone methide derived from 
11-deoxydaunorubicin with ethyl xanthate, two diastereomeric adducts, 11 
and 12, were isolated in an 85:15 ratio (Figure 7). 
11 
Mechanism for the Reductive Glycosidic Cleavage 
of Daunorubicin and Doxorubicin 
7 X - O H 
+ daunosamine 
Figure 6 
Dlastereomeric Adducts from Nucleophilic Trapping Experiment 
85 15 
Figure 7 
12 
On the other hand, Koch and Kleyer41 isolated, for the first time, the 
adduct formed from the electrophilic reaction of quinone methide 10 with 
benzaldehyde. Benzaldehyde reacted in what is nominally an aldol 
condensation to afford adduct 13 (Figure 8). 
Adduct from Electrophilic 
Trapping Experiment 
0 OH 
Figure 8 
The first report of the coupling of an anthracycline antitumor drug to a 
nucleophilic site in a nucleic acid was done by Egholm and Koch. 4 2 They 
described the successful coupling of menogaril (14) at the 7 position to 
2'-deoxyguanosine at the 2-amino position through a reductive activation 
(Figure 9). However, similar reduction of menogaril in the presence of a 
large excess of 2'-deoxyadenosine did not result in adduct formation. 
Continuing with these trapping experiments, Koch and co-workers 4 3 
were able to isolate, for the first time, adducts from the intramolecular 
trapping of the quinone methide derived from daunorubicin with oxygen and 
nitrogen nucleophilic sites. The oxygen and nitrogen nucleophiles were 
located at the 13 position of daunorubicin in oxime and semicarbazone 
derivatives. Thus, anaerobic reduction of daunorubicin oxime (15) and 
semicarbazone (16) with the one-electron reducing agent bi(3,5,5-tri methyl -
13 
2-oxomorpholin-3-yl) afforded cyclooxime 17 and cyclosemicarbazone 18, 
respectively (Figure 10). 
Reductive Coupling of Menogaril to 2'-Deoxyguanosine 
Figure 9 OH 
Intramolecular Trapping Experiment with O and N Nucleophlles 
2e* 
2H + 
OCH3O OH Odaunosamine 
15 Z - 0 
16 Z - - N - C O N H 2 
17 Z - O cyclooxime 
18 Z - - N H C O N H -
cyclosemicarbazone 
Figure 10 
14 
The importance of the reactivity of the quinone methide state with 
nucleophilic sites in nucleic acids remains obscure. 4 4 Although 
daunorubicin intercalates in duplex DNA,2 4* 4 5 once intercalated, its 
reduction is sterically inhibited.46"49 This, at least, explains in part the lack of 
correlation between covalent binding and antitumor activity. 
c. Generation oi Highly Reactive Superoxides by. Bioreductive Activation 
(One-electron Reduction Process). 
It has been demonstrated that rapid electron transfer from reduced 
anthracyclines to oxygen takes place under aerobic conditions.50 Goodman 
and Hochstein51 proposed that the observed lipid peroxidation caused by 
these agents is due to the generation of oxygen radicals via this redox 
process. Furthermore, Lown and co-workers 5 2 and Winterbourn and 
co-workers5 3*5 4 proposed that the oxygen radicals generated by the redox 
process may lead to oxygen-dependent DNA scission (Figure 11). 
Lown's group 5 2 added superoxide dismutase, catalase, and radical 
scavengers (i.e. sodium benzoate) to an incubation of covalently closed 
circular DNA and anthracyclines reduced in situ, in an attempt to identify the 
plausible oxygen radical involved in this process. Inhibition of the 
oxygen-dependent DNA scission was observed and this group identified 
superoxide ion and hydrogen peroxide radical as the active oxygen species. 
Lown's group strongly implicated the presence of hydroxide radicals as 
active oxygen species. 
Schreiber and co-workers5 5 detected, by high resolution electron spin 
resonance (ESR), the presence of anthracycline semiquinones in samples 
of both enzymatically and chemically reduced anthracyclines. This group 
15 
postulated the semiquinone form as an obligatory intermediate in the radical 
process. 
Mechanism for Oxygen-dependent DNA Scission 
O OH o OH OH 
1e 
H + 
OCH3O OH Odaunosamine 
1 
r 
lipid peroxidation; 
02-dependent DNA degradation 
Figure 11 
OCH3 O OH Odaunosamine 
semiquinone 
H 0 2 + 1 
Lown and co-workers56 postulated that the mechanism involved in the 
generation of oxygen radicals was linked to the dose-dependent 
cardiotoxicity of anthracyclines. This is because the heart tissue contains 
both mitochondrial and microsomal activating systems and is deficient in the 
protective enzymes superoxide dismutase, glutathione peroxidase, and 
catalase. 2 9 - 5 7 , 5 8 This provides the conditions which may account for the 
preferential susceptibility of this tissue to daunorubicin and doxorubicin. 
Evidence necessary to support this hypothesis was provided by Acton and 
co-workers 5 9 , 6 0 and Lown and co-workers. 6 1* 6 3 These two groups 
synthesized several glycosides modified at the anthraquinone chromophore, 
16 
the redox center of anthracyclines, with reduced or suppressed ability to 
undergo redox activation. Unfortunately, an undesirable concomitant 
reduction in the antitumor activity was also observed. Only the imino analog 
19 (Figure 12) showed comparable activity to daunorubicin at higher 
optimal doses. 
5-lminodaunorubicin 
OCH3 NH OH Odaunosamine 
19 
Figure 12 
This approach has showed some moderate success; however, there is 
no clear evidence that cytotoxicity can be dissociated from cardiotoxicity. 
d. Interaction with Topoisomerase H/DNA Complex. 
DNA topoisomerases are a unique class of enzymes which alter the 
topological state of DNA by breaking and rejoining the phosphodiester 
backbone of D N A . 6 4 ' 6 8 These enzymes catalyze DNA 
relaxation/supercoiling, catenation/decatenation, and knotting/unknotting 
reactions.66 Based on fundamental differences in their reaction mechanisms, 
DNA topoisomerases are classified into two types. Type I DNA 
topoisomerases alter the topological state of DNA by transiently breaking 
one strand of the DNA double helix and allowing the adjacent DNA strands 
to rotate around the phosphodiester bond opposite the nick before 
17 
resealing. Type II DNA topoisomerases break both strands of the helix, with 
a four base pair stagger between the cuts, and allow a second DNA duplex 
to pass through the break prior to resealing. This reaction requires ATP 
hydrolysis. 
Topoisomerases form a covalent protein-DNA complex during their 
reactions. In the case of topoisomerase I, this covalent complex involves a 
phosphotyrosyl bond between the enzyme and the 3' terminus of the break 
s i te . 6 9 - 7 0 On the other hand, topoisomerase II forms a phosphotyrosyl bond 
with each 5' terminus. 7 1 , 7 2 
DNA topoisomerase II has recently been identified as the primary 
intracellular target for a number of antitumor drugs currently being used in 
cancer chemotherapy,7 3'7 6 including the anthracyclines. The interactions of 
these drugs with topoisomerase II and cellular DNA produces the primary 
lesion involved in cytotoxicity and other cellular responses such as sister 
chromatid exchanges and chromosomal aberrations. 
Studies in both purified systems using DNA topoisomerase II and 
cultured mammalian cells have shown that these antitumor drugs interfere 
with the breakage-reunion reaction of DNA topoisomerases II. These drugs 
trap a key enzyme-DNA intermediate, termed the "cleavable complex" 
(Figure 13). 7 2 , 7 3 , 7 5 - 7 7 It has been proposed that these topoisomerase II 
targeted drugs alter the equilibrium between noncovalent topoisomerase 
ll-DNA complex and the cleavable complex, which results in an increased 
concentration of the latter.73 
18 
Model for Topoisomerase II Mediated DNA Cleavage and Cell Death 
i 
Cell Death 
(A) Unbound DNA topoisomerase II and substrate DNA. (B) 
Reversible formation of a noncleavable complex. (C) Reversible 
formation of a drug-induced cleavable complex containing 
topoisomerase II, DNA, and intercalative topoisomerase ll-targeting 
antitumor drug. (D) Processing of the cleavable complex by cellular 
functions resulting in cell death. 
Figure 13 
19 
The rapid cell killing caused by these agents is believed to be caused by 
induction and stabilization of the cleavable complex, rather than the 
inhibition of the catalytic activity of topoisomerase II. However, the cellular 
mechanism which translates the rapid formation of reversible complexes into 
a sequence of events that ultimately causes cell death is unclear. 
Structure-activity studies of drugs from the same chemical class showed 
a strong correlation between cytotoxicity and the ability of the drug to induce 
cleavable complexes.72 Anthracycline analogs that intercalate into DNA, and 
do not induce cleavable complex formation, do not cause rapid cell killing.73 
This fact strengthens belief in the interaction of anthracyclines with 
topoisomerases, rather than the intercalative proporties of these agents, as 
the mechanism of action of these antitumor drugs. However, they may both 
contribute. 
e. gall Membrane Surface Interaction-
The anthracycline drug doxorubicin has been shown to affect a number 
of membrane activities, including lectin interaction, 7 8 glycoprotein 
b iosynthes is , 7 9 phospholipid structure and organization, 8 0 and 
transportation of small molecules and ions.8 1 Based on these findings, the 
surface of the cell membrane was proposed as a possible extracellular 
target of the anthracyclines, and this interaction could lead to cytotoxicity. 
Tritton and co-workers 8 2 ' 8 4 carried out a study which involved doxorubicin 
and other anthracyclines covalently attached to insoluble polymeric matrixes 
that were larger than L1210 leukemia cells (Figure 14). Doxorubicin was 
coupled to cross-linked agarose beads, presumably by the amino group of 
the sugar, through carbamate bonds 8 2 and to cross-linked polyvinyl alcohol 
20 
supports activated with cyanuric chloride.84 Carminomycin was presumably 
anchored through ring D to cross-linked polyvinyl alcohol supports activated 
with diazonium salts.8 4 
Polymer-bound Anthracyclines 
HO 
Figure 14 
These preparations produced cytotoxicity to cells under conditions 
where no anthracycline drug entered them. This group concluded from this 
21 
study that anthracyclines can exert a cytotoxic effect solely by interaction at 
the cell surface. 
The mechanism by which the polymer-bound anthracyclines may 
ultimately lead to cell death is not clearly understood. 
In summary, the biologically active anthracyclines may exert a cytotoxic 
effect by a combination of different and parallel modes of action. Evidence 
has been accumulated which supports each of the mechanistic pathways, 
but additional studies must be performed to choose between them. 
3. Structure-Activity Relationships. 
The clinical importance of doxorubicin and daunorubicin, together with 
its serious side effects, has provided a powerful stimulus for the search for 
superior analogs. In order to find the most improved analog, the most potent 
and least cardiotoxic, hundreds of analogs have been prepared to establish 
the minimal structural requirements for biological activity. Some of these 
analogs have been prepared semi-synthetically, while others by total 
synthesis. Numerous modifications have been performed to find this 
improved analog,8 5 as a consequence, a great number of analogs have 
been synthesized and the field is rich in extensive authoritative reviews. 8 6' 8 9 
Because of the plethora of examples found in the literature, only those 
analogs considered pertinent to this work, in addition to the most successful 
derivatives, will be discussed. 
& Modifications in the Alicyclic Ring A. 
The 13-dihydroanthracyclines (see Figure 15 for modifications) 
displayed substantial antitumor activity similar to the parent agents in 
22 
different test systems (P388; Gross leukemia; sarcoma 180). 9 0 - 9 1 However, 
higher doses were necessary to achieve comparable cytotoxic potency. 
These derivatives were made by reduction of the carbonyl moiety at carbon 
13 via mic roorgan isms 9 2 or chemical reagents . 9 3 These 
13-dihydroderivatives are also found to be the major metabolic products of 
daunorubicin and doxorubicin.94 
Modifications In the Allcyclic Ring A 
H, OH; H, H; -N-NHCOR; «N-OH 
The presence of an ethyl side chain in a large number of naturally 
occurring anthracyclines such as aclacinomycin A (Figure 2), led to the 
complete reduction of the C-13 carbonyl group in daunorubicin and 
doxorubicin. These 13-deoxy derivatives showed comparable activity to that 
of the parent agents in the P388 screen, but optimal doses were higher.95 
Derivatization at the C-13 carbonyl (semicarbazone and oxime deriva-
tives) generally resulted in analogs with reduced antitumor activity. 9 0 ' 9 6 
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Formation of ester derivatives at the C-14 hydroxyl group of doxorubicin 
gave analogs which retained significant levels of antitumor activity against 
Gross leukemia, P388, and L1210 tumor cells. 9 7 These derivatives may be 
acting as pro-drugs of doxorubicin, which is released after enzymic 
hydrolysis. 
Substitution of the C-9 hydroxyl group by a hydrogen atom gave 
analogs which showed similar activity to that of daunorubicin, but 6-fold 
higher doses were required. 9 8 ' 9 9 
b. Modifications iatba Anthraquinone Chromophore-
Figure 16 shows the modifications which led to retention or increase 
antitumor activity. 
Modifications In the Anthraquinone Chromophore 
H 
HO 
Figure 16 
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Analogs with substantial retention of antitumor activity were obtained 
after modifications in the phenolic substitution pattern of the anthraquinone 
nucleus, primarily at positions 4, 6, and 11. 
The 4-demethoxy series of analogs was produced when the 4-methoxy 
group was substituted by a hydrogen atom. This series was achieved 
exclusively by total chemical synthesis, 1 0 0" 1 0 2 since carbon 4 is hydroxylated 
in all known biosynthetic anthracyclines. 4-Demethoxydaunorubicin 
(4-DMDA) and 4-demethoxydoxorubicin (4-DMDX) were equally or more 
effective than the parent anthracyclines when tested in different cultured 
cells, leukemia, and sarcomas. 1 0 0 , 1 0 3 4-DMDA showed remarkable activity 
via oral administration.104 In addition, this analog showed less severe 
cardiotoxic effects than doxorubicin at equiactive doses in mice and 
rabbits.1 0 5 This 4-demethoxy analog is currently available on the market as 
idarubicin and is indicated for acute non-lymphocytic and acute lymphocytic 
leukemias, and acute myeloid leukemia. 1 0 6 , 1 0 7 This drug is also reportedly 
active in daunorubicin-resistant patients, breast cancer, Hodgkin's and 
non-Hodgkin's lymphoma. 1 0 6 , 1 0 7 
The 11-deoxyanthracyclines were first isolated from a mutant strain of S. 
peucetius and these analogs showed significant biological activity, although 
higher optimal doses were required to achieve the same magnitude of 
antitumor activity.1 0 8 Finally, a few derivatives where the phenolic moiety at 
C-6 has been replaced by a hydrogen atom have also been prepared. 1 0 9 
6-Deoxycarminomycin has shown promising antitumor activity within this 
new series. 1 1 0 
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c. Modifications in the Sugar Residue. 
Modifications in the aminosugar moiety which led to retention or 
increase in antitumor activity are shown in Figure 17. 
Modifications In the Aminosugar Moiety 
epi OH; H, H 
Figure 
Removal of the aminosugar moiety by acid hydrolysis1 1 1 leaves the 
isolated aglycone portion, which is completely devoid of antitumor activity. 
This indicates that the presence of a sugar is a sine qua non structural 
feature for the expression of activity. 
New analogs were prepared by the coupling of the aglycone portions of 
daunorubicin and doxorubicin with configurational isomers of daunosamine 
at the C-3' and C-4' posit ions. 1 1 2 - 1 1 3 The L-xylo (C-3* epimer) derivatives 
were completely devoid of antitumor activity on the L1210 experimental 
leukemia in mice at the highest dose tested, while the L-ribo (C-3', C-4' 
di-epimer) analogs showed decreased activity when compared to the parent 
glycosides. However, the L-arabino (C-4' epimer) analogs fully retained the 
cytotoxic activity of the parent compounds at comparable doses. 1 1 2 * 1 1 5 
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Because these preliminary results were promising, the 4'-epidoxorubicin 
analog was subjected to additional studies against experimental tumors, 
and after significant clinical evaluation, this derivative seems to be a better 
tolerated and less toxic drug. 1 1 0 
Little or no antitumor activity was displayed by anthracycline analogs 
with the unnatural p-glycosidic bond (C-V epimer). 1 1 6 However, the 
p-anomer of 4-DMDA showed antitumor activity similar to that of 
daunorubicin, but the optimal doses were higher.1 1 6 
Remarkably active analogs were obtained when the C-4* hydroxyl group 
was substituted by a hydrogen atom. 1 1 7 4'-Deoxydaunorubicin and 
4'-deoxydoxorubicin analogs showed antitumor activity equal to that of the 
parent drugs on the L1210 leukemia in mice. The results against solid tumor 
(sarcoma 180) were more promising and exciting because 
4'-deoxydoxorubicin displayed similar activity to that of doxorubicin at lower 
optimal doses. The clinical evaluation of this analog has been reviewed.1 1 6 
Furthermore, these studies also indicated that new promising drugs with full 
retention or increase biological activity might be obtained by modification at 
the A'-posit ion. 
Numerous modifications have been performed at the amino functionality 
of the sugar, modifications which include amide formation,96* 1 1 9 and 
derivatization to secondary and tertiary amines. 1 2 0 - 1 2 1 The N-trifluoroacetyl 
analogs have shown antitumor activity, but significantly higher doses were 
required to obtain the same level of potency as the parent drugs. 
The 3-cyanomorpholino analog 20 (Figure 18) showed, in both cell 
cultures and murine experimental leukemias, to be 100-1000 fold more 
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potent than doxorubicin.1 2 1 This analog is the most potent anthracycline 
known to date and 20 may be less cardiotoxic than doxorubicin according to 
preliminary in vivo data. This agent is undergoing exhaustive clinical 
evaluation. 
3'-Deamlno-3'-(3-cyano-4-morphollnyl)doxorublcln 
20 
Figure 18 
In summary, biological activity is lost when the sugar residue is removed 
by hydrolysis. The alicyciic ring A can be modified without significant loss in 
activity, although the C-9 carbonyl and hydroxyl groups are required for 
maximal activity. Modifications of the phenolic substitution pattern of the 
anthraquinone chromophore and at the C-3' and C-4' positions of the 
aminosugar residue give analogs which display the same, or even greater, 
antitumor activity. 
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B. Design of A-Homoanthracycline Analogs of 
4-Demethoxydaunorubicin (Idarublcin) 
The anthracycline field has received a great deal of interest and has 
been the focus of intense research since the isolation of daunorubicin and 
doxorubicin. The discovery of these compounds as remarkable cytotoxic 
agents and the development of dose-dependent cardiotoxicity stimulated 
researchers to perform extensive systematic modifications and 
dehvatizations of these drugs in order to obtain new analogs with greater 
antitumor activity and lower cardiotoxicity. 
As described in the previous section, these modifications afforded a 
plethora of new analogs, among which idarubicin, 4'-epidoxorubicin, and 
3'-deamino-3-(cyano-2-morpholinyl)doxorubicin emerged on top because of 
the remarkable antitumor activity these analogs possess. Unfortunately, 
every class of drugs reaches a plateau or saturation level and this one is not 
an exception. The synthesis and discovery of new anthracyclines has 
declined during the last few years; therefore, it is necessary to design and 
synthesize novel analogs of doxorubicin and daunorubicin which may help 
us to find new or underexplored directions in this area. Thus, our objective is 
the design and synthesis of A-homo analogs of idarubicin (4-DMDA), which, 
if successful, will open new trends for the underexplored ring A of the 
anthracyclines. 
We chose to make derivatives of idarubicin (4-demethoxydaunorubicin) 
because of the low cardiotoxicity and high potency of this compound in 
comparison with the parent drugs. Furthermore, from a synthetic point of 
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view, the absence of the methoxy group makes the synthetic approach more 
facile. 
Our group has been engaged in the total synthesis of new analogs of 
4-DMDA modified at the alicyclic ring A . 1 2 2 ' 1 2 4 Among our earlier studies, we 
succeded in the synthesis of the 8-noraglycone of 4-DMDA. 1 2 3 During the 
course of this synthesis an intramolecular Claisen-Schmidt condensation 
which gave unexpected results was encountered. 
The Claisen-Schmidt condensation of benzaldehyde derivative 21 in 
the presence of K2CO3 in methanol afforded a mixture of the desired 
five-membered ring enone 22 and the seven-membered ring isomer 23 in 
31 and 51% yield, respectively (Scheme 1). The mechanism and the 
electronic factors which control this reaction have been studied and 
explained.1 2 5 
21 22 23 
31% 51% 
Scheme 1 
This unprecedented and unexpected outcome opened a new direction 
in the design and synthesis of novel anthracycline analogs, mainly, the 
9a-homo derivatives of 4-DMDA (24, Figure 19). 
30 
To expand the scope of this reaction and increase the number of 
A-homo analogs, a derivative with an 8a-homo methylene insertion was also 
designed (25, Figure 19). 
A-Homo Analogs of Idarubicin (4-DMDA) 
O OH 
O OH odaunosamine 
24 
Figure 19 
Synthetic analysis of these compounds indicated that the 9a-homo 
derivative was the intuitive analog to make as a consequence of the 
presence of a plane of symmetry. This element of symmetry would make the 
introduction of the hydroxyl group at the 7 position relatively simple. That is, 
this transformation could be carried out at either benzylic carbon because 
these positions were equivalent. On the other hand, the 8a-homo derivative 
was the counter-intuitive analog to make. 
Before we began the synthesis of these analogs, we utilized a series of 
molecular graphic modeling techniques (MACROMODEL 1 2 6 v. 2.3, 
SYBYL 1 2 7 v. 5.41) to study the ability of these compounds to intercalate into 
double helical DNA. 
Comparison of the MM2-minimized structures of these analogs with that 
of 4-DMDA showed that the aminosugar and the side chain moved 
significantly to a new area in these new analogs (Figure 20). As can be 
O OH odaunosamine 
25 
31 
seen, the extra methylene group in these A-homo analogs moved the side 
chain above the plane of the aromatic portion of these molecules. 
Modeling was caried out with a d(CpGpTpApCpG) hexamer of double-
helixcal DNA obtained from the X-ray crystal structure of the 
daunorubicin-DNA complex. 2 4 The intercalation was performed in the 
following manner: the daunorubicin structures were deleted from this 
complex and the MM2-minimized analogs were intercalated in lieu. An 
overlay of the minimized analogs with daunorubicin was done prior to the 
deletion, so as to obtain the same orientation that daunorubicin had in the 
DNA complex. In this manner, we assured almost the same spatial 
orientation of the intercalation portion, the side chain, and the sugar of the 
proposed analogs as that of daunorubicin (Figures 21 and 22). 
While conducting these computer graphics studies, it was found that the 
counter-intuitive analog 25 actually fit the intercalative model better than the 
9a-homo analog 24. As can be seen in Figures 21 and 22, the methyl 
ketone group of 25 is closer to the DNA than that of the 9a-ho mo analog. 
Thus, the carbonyl oxygen of the former can form hydrogen-bonding 
interactions with the base pair above the intercalator via a bridging water 
molecule. However, the methyl group of 25 is positioned so close to the 
base pair that might give rise to steric interactions not present in 24. 
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Overlay of the A-Homo Analogs with 4-DMDAU 
A 
B 
(A) Overlay of 4-DMDAU and the 8a-homo analog. (B) Overlay of 
4-DMDAU and the 9a-homo analog. 4-DMDAU in thick lines and 
A-homo anlogs in thin lines. 
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Figure 20 
Intercalatlve Modal of the 9a-Homo Analog 24 
• 
• 
• 
9a-Homo analog intercalated info the d(CGTACG) hexamer 
obtained from the X-ray crystal structure of daunorubicin-DNA 
complex. An overlay of the MM2-minimized analog with 
daunorubicin was done to obtain the same spatial orientation of 
24 as that of daunorubicin in the complex. 
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Figure 21 
Intercalative Model of the 8a-Homo Analog 25 
• • 
8a-Homo analog intercalated into the d(CGTACG) hexamer. The 
same spatial orientation of daunorubicin was obtained by an 
overlay of the MM2-minimized analog 25 with daunorubicin. 
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Figure 22 
Furthermore, these studies also showed that the conformation of the 
8a-homo analog is closer to that of the 6-membered analog. Thus, both 
series became our synthetic targets. 
Because of the intercalative property of these A-homo analogs, 
antitumor activity or cytotoxicity might be expressed via this property. These 
analogs could also express cytotoxicity by any of the other mechanisms 
mentioned before, that is, one- and two-electron bioreductive activation, 
inhibition of DNA topoisomerase, and/or interaction with the surface of cell 
membranes. 
C. Synthetic Analysis 
Scheme 2 shows the basic synthetic strategies employed in the 
preparation of racemic and optically active 4-demethoxy anthracyclines. The 
strategies employed can be classified in three basic groups: 
1. Preparation of a properly functionalized tetralin derivative which 
corresponds to rings AB, and subsequent annulation of rings CD by 
Friedel-C rafts acylation or Die Is-Alder reactions (pathway a in Scheme 2). 
2. Synthesis of tricyclic intermediates (BCD) and construction of ring A 
by cyclization of a suitably functionalized side chain, or by Diels-Alder 
condensation with the appropriate diene (pathway b). 
3. Construction of bicyclic BC intermediates and synthesis of rings A 
and D by Diels-Alder processes (pathway c). 
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Synthetic Strategies for the Preparation of 
4-Demethoxy Anthracyclines 
• Diels-Alder 
03 
Scheme 2 
The literature is filled with numerous representative examples of each of 
the above synthetic strategies, and extensive reviews have been 
publ ished. 8 6 - 8 9 ' 1 2 8 Analysis of the existing synthetic strategies indicates that 
the sensitive benzylic aminosugar moiety needs to be coupled to the 
aglycone portion during the final stages of the synthesis. This glycosidation 
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step has been performed by variations of the Koenigs-Knorr method with the 
suitably protected oc-daunosamyl chloride or bromide in the presence of 
mercury (II) 3 2 or silver ( I ) 1 0 2 - 1 2 9 - 1 3 0 salts. 
The syntheses of analogs 24 and 25 could be achieved employing any 
of the synthetic strategies described in the beginning of this section. Thus, 
compounds 24 and 25 were envisioned to be obtainable from the 
procedure which involves annulation of rings CD to the appropriately 
derivatized rings AB via a Friedel-Crafts acylation reaction. The 
retrosynthetic analysis is shown in Scheme 3. 
Based on the reviews of previous syntheses of anthracyclines, the first 
disconnection would take place at the glycosidic linkage. Because of the 
anticipated sensitivity of the sugar to a variety of acidic or basic conditions, 
the coupling of this moiety with agiycones 33 and 47 was planned late in 
the syntheses. 
Stereocontrolled introduction of the benzylic hydroxyl group at the 7 
position of deoxyaglycone 28 could afford the aglycone 33. Because of the 
plane of symmetry present in deoxyaglycone 28, we did not have to be 
concerned about regiochemistry. That is, introduction of the hydroxyl group 
could be performed at either benzylic position of 28. According to the 
literature, this transformation is achieved by radical bromination followed by 
solvolysis or its equivalent. Deoxyaglycone 28, in turn, would be 
synthesized via Friedel-Crafts acylation of the electron-rich benzocyclo-
heptenoi derivative 27 with phthalic anhydride. Derivative 27 would be 
prepared from the benzocycloheptenone derivative 26. 
38 
Retrosy nthetlc Analysis 
4 5 X - H 
Scheme 3 
Similar disconnections could be performed for analog 25. In this case, 
deoxyaglycone 45 would be obtained via Friedel-Crafts acylation of the 
benzocycloheptene derivative 44, which in turn, would be derived from the 
benzocycloheptenone derivative 26 followed by a 1,2-keto transposition. 
D. Synthesis of the 9a-Homo Analog 
Two different syntheses were devised for the preparation of analog 24 
(symmetric analog). The first route is based on the unexpected results 
previously obtained during the intramolecular Claisen-Schmidt cyclization. 
This synthesis was performed in collaboration with Professor Noboru 
Motohashi (Meiji College, Japan). The second route is a completely different 
synthesis, which includes a double alkylation reaction followed by acid 
hydrolysis and decarboxylation to obtain the common intermediate 26. 
The first synthesis (Scheme 4) started with the intramolecular 
Claisen-Schmidt condensation of the benzaldehyde derivative 21 under 
basic conditions to afford the seven-membered ring enone in 55% yield (the 
five-membered isomer was obtained in 37%). Catalytic hydrogenation over 
Pd/C gave the benzocycloheptenone derivative 26 in quantitative yield. 
Reaction of 26 with Baldwin's reagent at -78 °C afforded the bicyclic ketone 
27 in 56%. Friedel-Crafts acylation and demethylation of the phenolic 
hydroxyl groups, with the same reaction conditions, afforded the tetracyclic 
intermediate 28 in 50% overall yield. Currently, the synthesis of analog 24 
is under its way. 
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OCH 3 
OCH 3 o 
2 1 
0CH3 
OCH3 
27 
a K2CO3, MeOH, r.t. 1 h, 55% 
b. H2,Pd/C, 100% 
c. Baldwin's reagent*. -78 °C, acid-catalyzed hydrolysis, 56% 
d. AICI3, NaCI, heat, 50% overall 
'Baldwin's reagent: CH 2=C(Li)OCH 3 
Scheme 4 
The second approach (Scheme 5) started with 2,3-dimethyl-1,4-
dimethoxybenzene (29), which was prepared according to a literature 
procedure from 2,3-dimethyl p-hydroxyquinone.1 3 1 Benzylic bromination of 
29, under free radical conditions (NBS, hv), afforded the dibromo compound 
30 in quantitative yield. The benzocycloheptenone derivative 26 was 
obtained via a two-step reaction sequence. Reaction of 30 with dimethyl 
1,3-acetonedicarboxylate under basic conditions in acetone followed by 
acid-catalyzed hydrolysis and decarboxylation gave 26 in quantitative yield. 
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Synthesis of Rings AB of 9a-Homo Analog 24 
OCH 
a 
OCH, 
Br 
Br 
OCH 3 
30 
OCHg 
OCH 3 
26 
OCH3 OCH3 
a. NBS, hv, benzoyl peroxide, 100% 
b. i. dimethyl 1,3-acetonedicarboxylate, K 2 C0 3 , acetone 
ii. 4MH2S04/MeOH, reflux, 100% overall 
c. UC2-TMS/THF, -78 °C, 95% 
d. cat. HgO (yellow), 3M H2S04/THF, dark, 94% 
Scheme 5 
Treatment of 26 with (l-trimethylsilyl)ethynyl lithium in THF afforded 
alcohol 31 in 95%. Conversion of the acetylenic unit into a methyl ketone 
group was accomplished via a mercury(ll)-catalyzed hydration. Thus, 
treatment of 31 with yellow HgO catalyst and 3M H 2 S0 4 /THF gave 
compound 27 in 94%. In this manner, compound 27 completes the 
synthesis of rings AB of our anthracycline analog 24. 
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Next in our synthesis was the annulation of rings CD onto benzocyclo-
heptenol derivative 27 to obtain deoxyaglycone 28 (Scheme 6). In this 
manner, double acylation and demethylation of the phenolic hydroxyl 
groups were achieved, in one-pot reaction, via Friedel-Crafts acylation of 27 
with phthalic anhydride in 76% overall yield. 
o OH 
50 
a. phthalic anhydride, AICI3, NaCI. 185-187 °C, 76% overall 
b. acetic anhydride, pyridine, cat. DMAP, 90% 
c. i. DBDMH, hv, benzoyl peroxide; ii. AgOAc/HOAc/H20, dark; 
Hi. see Table 1 for hydrolysis conditions 
Scheme 6 
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Samples of 28 from both routes were analyzed by HPLC, 1 H NMR, and 
IR for comparison purposes. The results indicated that both samples were 
identical, and these results, therefore, confirmed both synthetic approaches. 
During the synthesis of 4-demethoxy-8-nordaunomycinone,123 it was 
found that acetylation of the phenolic hydroxyl groups facilitated the 
introduction of the benzylic hydroxyl group. A rationale for this decisively 
favorable effect on the reactivity invoked participation by the neighboring 
acetate moiety (anchimeric assistance). Backside displacement of the 
p-bromo group by the acetyl group, followed by solvolysis gave the desired 
c/s-glycol (Figure 23). Evidence for this explanation came from the observed 
migration of the phenolic acetate group involved in the neighboring group 
participation. 
O OAc 
o v 2 ^ ° 
H 2 0 - ^ * 
Figure 23 
Based on the favorable effect on stability and reactivity induced by the 
acetate esters, we decided to protect the phenolic hydroxyl groups as 
acetates instead of methyl ethers. Thus, reaction of deoxyaglycone 28 with 
acetic anhydride in pyridine and DMAP catalytic afforded the triacetate 32 in 
90% (Scheme 6). Besides the neighboring group participation of the acetate 
functionality, the triacetate derivative was much more soluble in CCI 4 than 
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the deoxyaglycone. When compounds with free phenolic hydroxyl groups 
were used as starting materials, their utility was limited to small-scale 
experiments as a consequence of their low solubility in CCI4. 
Procedures for the introduction of the benzylic hydroxyl group at the 7 
position of the anthracyclines are well established and have excellent 
precedents.8 6' 1 3 2 * 1 3 5 However, transformation of 28 to the aglycone 33 
proved to be impossible in our hands. We explored all known standard 
procedures, but the results were always unsatisfactory. 
Introduction of the benzylic hydroxyl group is generally done via a 
three-step process, without purification of the intermediates due to the 
instability of these compounds. Benzylic bromination of 28 with 
1,3-dibromo-5,5-dimethylhydantoin (DBDMH) and light (hv) gave the bromo 
derivative, which was carried directly onto the next step without further 
purification. In this manner, the reaction mixture was reacted with silver 
acetate in HOAc and H2O to give the substitution product. This latter was 
also taken onto the next step without further purification. The acetate was 
hydrolyzed under acidic or basic conditions to give the dehydrated product 
50, decomposition, or starting material (Scheme 6). The desired aglycone 
33 was never obtained. 
It is worth mentioning that from all the syntheses of DA, DOX, and 
4-DMDA reported in the literature, few of them have reached the final 
compound. Generally, these syntheses were stopped at the deoxyaglycone 
intermediate. The authors 1 3 6 ' 1 4 0 claimed that their work constituted a total 
formal synthesis of the target molecules because the subsequent 
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transformations had already been carried out and there was enough 
documentation in the literature to perform this sequence of reactions. 
Although these transformations have already been performed, these 
researches did not bridge the gap. The reason for this is that this series of 
reactions is not so trivial as reported in the literature. We know by our own 
experience and by findings of others1 4 1 that this series of reactions often do 
not work on big-scale experiments. Furthermore, in the synthesis of DA by 
Swenton and Raynolds, 1 3 7 the authors stated that they were not able to 
functionaiize the 7 position on a scale needed for subsequent work. 
In an effort to pin-point the problem, the unstable substitution product 
was isolated and partially characterized ( 1 H NMR and MS). The 
spectroscopic data indicated that the triacetate 48 was formed instead of the 
tetraacetate 49 (Figure 24). These findings indicated that the B-bromo 
group was displaced by the neighboring acetate group, followed by 
soivoiysis to give the isolated product 48. This process was similar to that of 
the 8-nor series with the exception that the 9 acetate group was the 
participating group in the anchimeric assistance instead of the phenolic 
acetate. 
o OAC O OAc 
48 49 
Figure 24 
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Triacetate 48 was subjected to different hydrolysis conditions as 
depicted in Table 1. Acid-catalyzed hydrolysis afforded the dehydrated 
product in entry # 2 and decomposition product(s) in entry # 3. Basic 
hydrolysis, on the other hand, afforded dehydration product, decomposition, 
or starting material. 
Table 1. Hydrolysis Conditions for the Introduction of the 
Benzylic Hydroxyl Group. 
Entry Reaction Conditions Results 
1 0.5M K2C03/acetone125 Decomposition 
2 3A7 HCI/MeOH 1 4 2 Dehydration 
3 0.5A/HCI/HOAC/THF143 Decomposition 
4 5% K2CO3 in Decomposition 
MeOrVH 20/THF 1 4 4 
5 0.1/VLiOH in Dehydration 
THF/H20/i-PrOH1 4 5 
6 MeOH/NaOMe1 4 6 Starting Material 
7 NH3/MeOH1 4 7 Decomposition 
8 anh. MeOH/pTsOH St. Mat. & Dec. 
or PPTS 1 4 8 
9 #5 + air Dehydration 
10 #5 + argon Dehydration 
11 0.5MK2CO3 /PCC 15 min St. Mat. 
30 min Dehyd. 
12 TPFPFeCI/Phl(OAc)2 1 4 9 Decomposition 
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A previous report 1 4 1 indicated that the benzylic position of the 
anthraquinone system was surprisingly inert to direct oxidation. Different 
oxidizing reagents were employed, ie lead tetraacetate, eerie ammonium 
nitrate, and SeC<2, but all of them gave only recovered starting material. 
However, Holland and Viski 1 4 9 reported a direct oxidation of the benzylic 
position of the intermediate 2-acetyl-5,8-dimethoxy-2-hydroxytetrahydro-
naphthalene by the use of a porphyrine derivative and Phl(OAc)2. 
Thus, treatment of compound 32 under conditions similar to those 
reported by Holland and Viski gave decomposition products and starting 
material (entry # 12). 
Formation of compound 50 could be rationalized by invoking a 
mechanism similar to that of the bioreductive activation of anthracyclines. 
Formation of the corresponding quinone methide followed by proton 
abstraction could have led to the formation of the dehydrated product 
(Scheme 7). To examine this hypothesis, we added PCC (oxidizing agent) 
or passed air into the solution in order to stop the formation of 50 (entries 5 
and 10). This was not observed, however. 
An alternative explanation for the formation of compound 50 could be 
through the putative intermediate orthoester 51 (Scheme 8). Under acidic 
conditions, 48 could form orthoester 51 (1,3-diaxial relationship of the 
hydroxy and acetate groups) which, in turn, eliminates (via an Ei process) 
the orthoacetate group to generate the double bond. 
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Scheme 7 
O OAc 
O OAc H 
Scheme 8 
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At this point, we do not have a conclusive explanation tor the formation 
of 50. More work is necessary for the better understanding of this series of 
reactions which, in turn, could lead to a better functionalization of the 
benzylic position. 
Because of the great amount of effort already spent in these 
transformations and lack of a better understanding of the mechanistic details 
occurring in this series of reactions, we decided to leave the synthesis at this 
stage and continue our work with the preparation of the 8a-homo analog in 
the hope of achieving a better result. 
E. 1,2-Keto Transposition 
In the retrosynthetic analysis of the 8a-homo analog, the 
benzocycloheptenol derivative 44 was envisioned to be derived from 
benzocycloheptenone 26 followed by a 1,2-keto transposition. 
The 1,2-keto transposition of 26 proved to be more difficult than 
anticipated. Standard procedures, such as enolsilylation, 1 5 0 ' 1 5 1 
1,2-(alkylative) carbonyl transposition,1 5 2 and Nakai's method, 1 5 3 failed in 
our hands. This transformation, however, was ultimately accomplished in six 
steps with an overall yield of 43% from 26. The key step was the 
regioselective opening of an epoxide (Scheme 9). 
Treatment of 26 with trisylhydrazide gave the corresponded hydrazone 
34 in 84%. Reaction of 34 with n-BuLi (Shapiro reaction) afforded the 
benzocycloheptene derivative 35 in 86%. Alkene isomerization was 
performed with RhCl3 3 H 2 0 in refluxing ethanol 1 5 4 to give 36 (88%). 
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Epoxidation was accomplished with dimethyldioxirane (0.1 M in acetone) in 
CH2CI2. 1 5 5 , 1 5 8 The epoxide was used without further purification and 
treatment with LAH followed by basic work-up afforded the 
benzocycloheptenol derivative 37 in 75% overall yield. Sometimes, alkene 
36 was also formed during the work-up, reducing the yield to 60%. 
Oxidation with PCC afforded, in 89% yield, the desired transposed ketone 
38. 
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1,2-Keto Transposition 
OCH 3 9 C H 3 
a 
a. NH2-NH-trisyl/HCI, 84% 
b. n-BuU/THF,-78 °C, 86% 
C. RhCI 3 3H20/CHCI3/EtOH, reflux, 88% 
d. i. dimethyldioxirane/CH2CI2; ii. LAH/THF, 75% overall 
e. PCC/acetone, 89% 
51 
Scheme 9 
F. Synthesis of the 8a-Homo Analog 
Once the 1,2-keto transposition was accomplished, we decided to find a 
more direct alternative route toward the ketone 38. This direct route utilizes 
a ring expansion reaction for the preparation of 38. 
The synthesis (Scheme 10) starts with compound 39 which was 
previously synthesized in our laboratories.157 Alkene isomerization of 39 
with RhCl3 3H 2 0 afforded the 1,2-dihydronaphthalene derivative 40 (90%). 
Formation of the a-tetraiol derivative 41 was accomplished in 77% when 40 
reacted with diborane followed by oxidation with H202/NaOH. The B-tetralol 
isomer was also formed in a 10:1 a:p selectivity ratio. Oxidation of 41 with 
PCC gave the corresponding ketone 42 in 87%. 
The ring expansion reaction 1 5 8 * 1 5 8 was performed in a two-reaction 
process. First, reaction of 42 with methyttriphenylphosphonium bromide and 
NaH in DMSO afforded an exo-methylene intermediate. Without purification, 
this intermediate was treated with T1(N03)3 in MeOH to afford 38 in 75% 
overall yield. 
At this point, we had to transform 38 into rings AB. To do this, a similar 
transformation used for the symmetric analog could be employed. However, 
38 is an easily enolizable ketone and, therefore, a less basic reagent must 
be employed. To avoid enolization by the lithium reagent, a cerium 
reagent 1 6 0 , 1 8 1 was used instead. 
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Synthesis of Rings AB of 8a-Homo Analog 25 
OCH3 0CH3 0CH3 
39 40 41 
O C H 3 0 OCH3 
0CH3 0CH3 
42 38 
OCH3 
44 
a. RhCI3 3H 20, CHCig/EtOH, reflux, 90% 
b. i. B2H6/THF; ii. HjOg/NaOH, 77% 
c. PCC/acetone, 87% 
d. i. MePh3PBr, NaH, DMSO; ii. TI(N03)3/MeOH, 75% overall 
e. Ce(C2-TMS)Cl2/THF, -78 °C, 100% 
f. cat. HgO (yellow), ZM H 2SO/THF 
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Scheme 10 
Thus, transformation of 38 to 44 was accomplished in the following 
manner (Scheme 10). Reaction of the seven-membered ring ketone with 
cerium [(1-trimethylsilyl)ethynyl]Cl2162 at -78 °C in THF gave the acetylenic 
alcohol 43 in 100% yield. When an enolizable reagent is used instead (Li 
and Mg reagents), this reaction works in 40% yield and one half of the 
starting material is recovered. Hydration of 43 was accomplished with 
yellow HgO catalytic in 3M H2SO4/THF to give rings AB in 87% yield. 
At this stage, we just needed to annulate rings CD onto rings AB to 
obtain the deoxyaglycone 45. This was accomplished using the same 
procedure employed in the conversion of 27 to 28. Thus, Friedel-Crafts 
acylation of 44 with phthalic anhydride gave 45 in 85% overall yield 
(Scheme 11). 
Next in our synthesis was the regio- and stereocontrolled introduction of 
the benzylic hydroxyl group at the 7 position. To control the regiochemistry, 
the methyl ketone group was protected as the ethylene ketal (Scheme 11), 
in order to increase its steric bulk. In this way, the ketal group is expected to 
hinder bromination at the 11 position, and at the same time to favor 
bromination at the desired 7 position. We anticipated stereocontrolled 
introduction of the hydroxyl group by the anchimeric assistance of the 
phenolic acetate group as described in the preceding discussion.1 2 3 
In this manner, deoxyaglycone 45 was treated with ethylene glycol and 
p-TsOH catalytic and azeotropic removal of water to give the protected 
ketone. Because of the high insolubility of this compound, the ketal was not 
purified and treatment with acetic anhydride, pyridine, and DMAP catalytic 
afforded the diacetate 46 in 90% overall yield (Scheme 11). 
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46 47 
a. phthalic anhydride, AICI3, NaCI, 180-182 °C, 85% overall 
b. i. HO(CH2)20H, cat. p-TsOH, PhH; ii. AcaO, Pyr, cat. DMAP, 90% overall 
c. see Table 1 for hydrolysis conditions 
Scheme 11 
Once this point was reached in our synthesis, we only needed one more 
intermediate before the final compound. However, formation of aglycone 47 
was exhaustively pursued without success. Again, we explored all the 
known procedures for this transformation (see Table 1), but all of our efforts 
did not help us to achieve our goal. It seems that the intermediates were 
much more labile even than those of the symmetric counterpart. In this case, 
no dehydrated product was formed, only decomposition products were 
obtained. 
Isolation of the substitution product was impossible. This indicated that 
in this series of reactions the problem resided in the bromination step. 
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Perhaps, the bromo derivative is much more unstable in the 8a-homo series 
than in the 9a series. 
Because of the great deal of effort, the amount of time consumed, and 
the idiosyncratic reactivity or unstability of the bromo compound 
intermediate, we decided to leave this synthesis at this stage, until more 
studies about this series of reactions are peformed to shed more light on the 
mechanisms of these reactions. 
G. Conclusions 
Computer graphic analyses indicated that the non-intuitive analog 25 
might be more active than the intuitive analog 24. Unfortunately, the power 
of computer graphic studies could not be corroborated, since the synthesis 
of these analogs could not be completed. 
Standard 1,2-keto transposition procedures proved to be more difficult 
than anticipated. At this stage of the synthesis, the compounds already 
started to show some idiosyncratic behavior. The route employed in our 
case had a regioselective opening of an epoxide as the key step. This 
transformation was accomplished in six steps with an overall yield of 43%. 
The syntheses of analogs 24 and 25 could not be finished due to the 
intractible behavior of some of the intermediates. Unfortunately, this 
intractible behavior could not have been anticipated during the design of the 
syntheses since no complications have been reported for the introduction of 
this functionality in the six-membered series. 
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These syntheses were left at the stage of advanced intermediates. So, if 
new strategies for the introduction of the benzylic hydroxyl group are 
discovered, hopefully these new procedures could be tried on these 
advanced intermediates for the completion of the syntheses. 
More studies must be conducted in order to understand and shed more 
light on the reactions needed for the functionalization of the 7 position. 
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EXPERIMENTAL 
Melting points were determined on a Thomas-Hoover capillary melting 
point apparatus and are uncorrected. Infrared (IR) spectra were obtained on 
an IBM FTIR 32 or a Perkin Elmer 1420 spectrophotometer. Proton nuclear 
magnetic resonance ( 1 H NMR) spectra were recorded on Varian XL-300 
(300 MHz) and Bruker AM-500 (500 MHz) spectrometers in the indicated 
solvents using tetramethylsilane as internal reference, unless otherwise 
specified. All chemical shifts are expressed in parts per million (5). Electron 
impact mass spectra (EIMS), chemical ionization mass spectra (CIMS), and 
high resolution mass spectra (HRMS) were obtained on a Varian CH-5 or 
Ribermag R10-10 mass spectrometer by Dr. Charles Judson, Dr. Todd 
Williams, Dr. Tho I. Nguyen, and Robert Drake. Microanalyses were 
performed by Dr. Tho I. Nguyen on a Hewlett-Packard Model 185 CHN 
analyzer at the University of Kansas, or by Midwest Microlab, Ltd., 
Indianapolis, IN. Ultraviolet (UV) spectra were recorded on a Hewlett-
Packard Diode Array 8450A. Flash chromatography and medium pressure 
liquid chromatography (MPLC) were performed on Merck silica gel (230-
400 mesh), and gravity column chromatography on Merck silica gel (70-270 
mesh). Preparative centrifugal thin-layer chromatography (PCTLC) was 
performed on a Harrison Model 7924 Chromatotron using Merck silica gel 
60 PF-254 containing CaSC-4 1/2 H 2 0 binder. "Workup" indicates drying 
over anhydrous l ^ S C U , filtration, and concentration in vacuo. 
5,8-Dimethoxy-1,4-dihydronaphthalene167 (39) and 1,4-dimethoxy-2,3-
dimethylbenzene131 (29) were prepared via literature procedures. Reagents 
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and solvents were used as obtained without further purification unless 
otherwise indicated. Bulk grade solvents: diethyl ether, hexanes, acetone, 
and methanol were distilled before use. Tetrahydrofuran (THF) and diethyl 
ether (Et20) were distilled immediately before use from sodium 
benzophenone ketyl. Methylene chloride (CH2CI2) was distilled immediately 
before use from phosphorus pentoxide. Benzene was distilled from 
powdered calcium hydride. Methanol (MeOH) and ethanol (EtOH) were 
distilled from Mg turnings. Anhydrous carbon tetrachloride (CCI4) and 
anhydrous pyridine were purchased from Aldrich Chemical Co. 
N-bromosuccinimide (NBS) was recrystallized from ten parts of water. 
All reactions involving moisture- or oxygen-sensitive materials were 
performed in flame- or oven-dried glassware under a positive pressure of 
argon. 
2,3-Bis(bromomethyl ) -1 ,4 -d Imethoxybenzene (30). A mixture of 
2,3-dimethyl-1,4-dimethoxybenzene (5.00 g, 30.1 mmol), NBS (11.24 g, 63.1 
mmol), and benzoyl peroxide (50 mg) in anhydrous CCI4 (150 mL) was 
refluxed with irradiation, using a sunlamp for 8 h. After the mixture cooled, 
the succinimide was filtered off and the solvent was evaporated under 
reduced pressure. The residue, upon crystallization from CH2Cl2-hexanes, 
furnished the dibromide 30 as off-white needles (9.68 g, 99%): mp 153.5-
154 °C (lit . 1 6 3 149 °C; l it . 1 6 4 147-149 °C). 1 H NMR and IR data agree with 
reported va lues . 1 8 3 ' 1 6 4 
1 , 4 -D imethoxy -5 ,6 ,8 ,9 - te t rahydro -7H -benzocyc lohepten -7 -
o n e (26). A mixture of 30 (9.35 g, 28.9 mmol), dimethyl 1,3-
acetonedicarboxylate (5.02 g, 28.9 mmol), and K2CO3 (8.37 g, 60.6 mmol) in 
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dry acetone (100 mL) was stirred at room temperature under Ar for 8 h. The 
mixture was filtered and concentrated under reduced pressure. The solid 
obtained was redissolved in MeOH (120 mL), AM H2SO4 solution (15 mL) 
was added and the reaction mixture was refluxed overnight. After the mixture 
cooled, it was diluted with water (100 mL) and the solid obtained was filtered 
off and dried under high vacuum at 35 °C to afford 26 in quantitative yield. 
Analytical sample was obtained by recrystallization from hexanes to give 
pale yellow flakes: mp 123.5-124 °C (lit. 1 6 5 124-125.5 °C). 1 H NMR and IR 
data agree with reported values. 1 6 5 
1,4-Dimethoxy-7-(trimethylsilyl)ethynyl-6,7,8,9-tetrahydro-
5H-benzocyc lohepten -7 -o l . (31) . To a cold solution (-20 °C) of 
trimethylsilylacetylene (267.6 mg, 2.72 mmol) in THF (20 mL) was added 
dropwise n-BuU (1.6M in hexanes, 1.6 mL 2.50 mmol) and the mixture was 
stirred at this temperature for 15 min. After this, it was cooled to -65 °C and a 
solution of ketone 26 (500 mg, 2.27 mmol) in THF (20 mL) was added 
dropwise. After the mixture was stirred for 45 min at this temperature and for 
another 15 min at room temperature, it was poured into sat. aq. NH4CI (20 
mL). The layers were separated, the aqueous layer was extracted with ether 
(2x10 mL), and the combined organic extracts were worked up to afford 31 
as a yellowish white solid (684.9 mg, 95%). Analytical sample was obtained 
by recrystallization from ether-hexanes: mp 121-121.5 °C; UV (CH3CN), 
Xmax (e) 224 (7 560, sh), 289 (3 630) nm; IR (CHCI3) 3580 (sharp). 3000, 
2940, 2810. 2130. 1580. 1480, 1460, 1340, 1250, 1080. 1040, 900, 850 
cm*1; 1 H NMR (500 MHz, CDCI3) 66.690 (s, 2H), 3.761 (s, 6H), 3.234 (br s. 
2H), 2.668 (brs, 4H), 1.961 (br s, 1H, D 2 0 exch.), 0.169 (s, 9H); EIMS mlz 
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(relative intensity) 319 (M+ + 1, 19), 318 (M+, 93), 300 (15), 285 (14), 269 
(18), 227 (13), 163 (19), 99 (29), 73 (100), 45 (37). 
Anal. Calcd for Ci 8H 2603Si: C, 67.88; H, 8.23. Found: C, 67.78; H, 8.40. 
7-Acetyl-1,4-dimethoxy-6,7,8,9-tetrahydro-5H-benzocyclo-
hepten-7-ol (27). A solution of 31 (250.0 mg, 0.78 mmol) in THF (10 mL) 
was added dropwise to a solution of yellow HgO in 3M H 2 S 0 4 (6 mL). The 
mixture was stirred at room temperature in the dark under Ar for 5 h. After 
this time, the mixture was diluted with water (50 mL), extracted with CH2CI2 
(3 x 100 mL), and the combined organic layers were worked up. Purification 
by MPLC (EtOAc-hexanes 1:4) afforded 27 as a yellowish white solid (195.5 
mg, 94%). Analytical sample was obtained by recrystallization from ether-
hexanes: mp 117-117.5 °C; UV (CH3CN), Xmax (e) 208 (7 350), 225 (3 110, 
sh), 290 (1 380) nm; IR (CHCI3) 3470 (sharp), 3000, 2940. 2830, 1700, 
1600, 1480. 1340. 1240, 1170, 1080, 1035, 950, 900, 800 cnr»; 1H NMR 
(500 MHz, CDCI3) 6 6.690 (s, 2H), 3.888 (s, 1H. D 2 0 exch.) 3.755 (s, 6H), 
3.268 (ddd, Jm 14.6. 6.7,2.5 Hz, 2H), 2.912 (ddd, J = 14.8,10.4, 2.9 Hz, 2H), 
2.117 (s, 3H), 1.742-1.682 (m, 4H); EIMS mlz (relative intensity) 264 (M+, 
15). 221 (33), 203 (7), 191 (9), 177 (10), 151 (33), 91 (14), 77 (13), 43 (100). 
Anal. Calcd for C15H20O4: C, 68.16; H, 7.63. Found: C, 68.50; H. 7.68. 
4 -Demethoxy -7-deoxy -9a-homodaunomycinone (28). A n 
intimate mixture of 27 (1.50 g, 5.68 mmol). phthalic anhydride (2.52 g, 17.03 
mmol), AICI3 (16.65 g, 124.85 mmol), and NaCI (3.65 g, 62.43 mmol) was 
placed in a beaker and immersed in a sand bath pre-heated at 185-187 °C. 
The mixture became a dark red melt instantly and It was stirred continously 
with a rod glass for 6 min. After the reaction mixture was allowed to cool, a 
61 
sat. aq. solution of oxalic acid (10 mL) was added cautiously until no HCI 
gas evolved. Next, 50 mL of the sat. solution were added and the resulting 
mixture was heated for 10 min at 80 °C. The red precipitate was filtered off, 
redissolved in CHCI3 (250 mL), filtered through celite, and concentrated 
under reduced pressure. The purple solid obtained was purified by MPLC 
(EtOAc-hexanes 1:2) to afford 28 as a red-orange solid (1.59 g, 76%). 
Analytical sample was obtained by recrystallization from CHCI3 to give an 
orange solid: mp 238.5 °C dec.; UV (CH3CN), X m a x (e) 205 (28 080), 230 (13 
480), 252 (41 160 sh), 257 (46 080). 292 (7 440) nm; IR (CHCI3) 3350 (br), 
2940, 1700. 1615, 1585, 1405, 1375, 1345, 1255, 1090, 905cm-l; 1H NMR 
(500 MHz, CDCI3) 13.667 (2H, D 2 0 exch.), 8.352 (dd, J = 5.9, 3.3 Hz, 2H), 
7.815 (dd, J - 5.9, 3.4 Hz, 2H), 3.980 (s, 1H, D 2 0 exch.), 3.496 (t; dd, J - 4.3; 
5.4, 2.6 Hz. 2H). 3.050 (dt, Jm 14.1,6.8 Hz, 2H), 2.161 (s, 3H), 1.770 (brt, J « 
4.3 Hz, 4H); EIMS mlz (relative intensity) 367 (M+ + 1, 3), 366 (M+. 11), 324 
(21), 323 (98), 305 (14), 281 (14), 187 (14), 77 (12), 43 (100). 
Anal. Calcd for C21H18O6I/2H2O: C, 67.20; H, 5.10. Found: C, 67.40; H, 
4.80. 
4-Demethoxy-7-deoxy-6,9,12-triacetyl-9a-homodaunomyci-
none (32). To a solution of 28 (370.0 mg, 1.01 mmol) and DMAP (2-3 mg) 
in pyridine (12 mL) was added acetic anhydride (3.43 mL, 36.4 mmol). The 
reaction mixture was stirred for 1 h at room temperature and then 
concentrated under high vacuum to afford a dark yellow solid. Purification by 
MPLC (EtOAc-hexanes 1:1) afforded 32 as a yellow solid (445.3 mg, 90%): 
mp 243-244.5 °C dec.; UV (CH3CN), W (c) 258 (30 370), 280 (10 180), 
344 (5 425) nm; IR (CHCI3) 2940, 1760, 1730, 1710, 1670, 1580, 1430, 
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1370, 1330, 1290, 1240, 1180, 1060, 1010, 940 cm- 1 ; 1 H NMR (500 MHz, 
CDCI3) 6 8.127 (dd, J = 5.8, 3.3 Hz, 2H), 7.716 (dd, J - 5.8, 3.3 Hz, 2H), 
3.035 (dd, J m 15.0,7.7 Hz, 2H), 2.898 (app. t, J « 14.6 Hz, 2H), 2.505 (s, 6H), 
2.368 (br s, 2H), 2.174 (s, 3H), 2.092 (s, 3H), 1.819 (brt, J * 13.0 Hz, 2H); 
CIMS (NH3) mlz (relative intensity) 510 (M++ 18, 21), 493 (M++ 1,19), 451 
(26), 408 (11), 390 (18), 348 (47), 306 (22), 43 (100). 
Anal. Calcd for C27H24O9: C, 65.85; H, 4.91. Found: C, 65.96; H, 5.13. 
4-Demethoxy-7,8-dehydro-9a-homodaunomycinone (50). A 
mixture of 32 (50.0 mg, 0.102 mmol), 1,3-dibromo-5,5-dimethylhydantoin 
(29.0 mg, 0.102 mmol), and benzoyl peroxide (10 mg) in anhydrous CCI4 
(12 mL) was refluxed with irradiation, using a sunlamp for 2 h. After the 
mixture cooled, the solvent was removed under reduced pressure and the 
solid obtained was re-dissolved in HOAc (5 mL). Silver acetate (42.4 mg, 
0.254 mmol) and H 2 0 (0.21 mL) were added and the mixture was stirred in 
the dark for 12 h. After this period, the reaction mixture was concentrated 
under high vacuum and the solid obtained was purified by MPLC 
(EtOAc-hexanes 1 2) to afford the unstable intermediate 48 (17.7 mg, 34%). 
After partial characterization ( 1 H NMR, MS), compound 48 was suspended 
in MeOH-H 2 0 (2:1, 12 mL), 1 mL of 6N HCI was added and the reaction 
mixture was refluxed under Ar for 72 h. After this time, the mixture was 
diluted with H 2 0 (20 mL) and extracted with CHCI3 (3 x 15 mL). The 
combined organic layers were washed with brine (15 mL) and worked-up. 
Purification by MPLC (EtOAc-hexanes 1:4) afforded 50 as an orange-red 
solid (6.2 mg, 58%). 
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48:1H NMR (500 MHz, CDCI 3) 8 8.147-8.121 (m, 2H), 7.732-7.713 (m. 
2H), 6.805 (br s. 1H), 2.851 (br s, 1H), 2.527 (s, 6H), 2.482 (s, 3H), 2.276-
2.151 (m, 2H), 2.082 (s, 3H), 1.927 (br s, 4H); CIMS (NH 3) mlz (relative 
intensity) 508 (M+, 6), 450 (1), 415 (2). 389 (5), 347 (4), 187 (2), 105 (3), 91 
(2), 43 (100). 
50: mp 215 °C dec.; UV (EtOH), W (e) 209 (19 840), 266 (41 700) nm; 
IR (CHCI3) 3360-3500 (br), 2920, 2840, 2360. 2340, 1715, 1620, 1590, 
1455, 1395, 1345, 1320, 1290, 1245. 1125. 1085, 965 cnr>; lH NMR (500 
MHz, CDCI3) 5 13.904 (s, 1H, D 2 0 exch.), 13.637 (s, 1H, D 2 0 exch.), 8.354-
8.336 (m, 2H), 7.833-7.815 (m, 2H), 7.260 (d, J - 12.6 Hz, 1H), 5.944 (dd, Jm 
12.6, 2.3 Hz. 1H). 4.520 (s. 1H, D 2 0 exch.), 3.764 (dd, Jm 15.1, 7.7 Hz, 1H), 
2.538 (dd, Jm 15.2,11.1 Hz, 1H), 2.149 (s, 3H), 2.084 (ddd, Jm 14.2, 7.8, 2.2 
Hz, 1H), 1.975 (dd, Jm 14.3,11.3 Hz, 1H); EIMS mlz (relative intensity) 364 
(M+, 4), 346 (4), 321 (100), 303 (17), 187 (15), 105 (11), 43 (96). 
HRMS Calcd for C21 H i 6 0 6 : 364.0947. Found: 364.0944. 
1,4-Dimethoxy-5,6,8,9-tetrahydro-7H-benzocyclohepten-7-
one trisylsulfonylhydrazone (34). To a stirred suspension of finely 
ground trisylhydrazide (6.77 g, 22.7 mmol) in 30 mL of methanol was added 
the ketone 26 (5.00 g, 22.7 mmol). The addition of 0.5 mL of cone. HCI 
caused the mixture to clear rapidly, after which a fine granular product 
began to crystallize. The reaction mixture was chilled overnight and filtered. 
The product was washed with cold methanol and dried under vacuum at 
room temperature to afford 34 as a white solid (9.49 g, 84%). Analytical 
sample was obtained by recrystallization from CH2Ci2-hexanes to give white 
crystals: mp 163 °C dec.; UV (CH3CN), Xmax (e) 260 (6 1250), 286 (5 150) 
64 
nm; 1H NMR (500 MHz, CDCI 3) 8 7.185 (s 1H, D 2 0 exch.), 7.133 (s, 2H), 
6.662 (s, 2H), 4.235-4.181 (m, 2H), 3.737 (s, 3H), 3.707 (s, 3H), 2.933-2.874 
(m, 4H), 2.480-2.455 (m, 2H), 2.372-2.348 (m, 2H), 1.238 (d, J - 2.9 Hz, 9H), 
1.224 (d, J - 2.5 Hz, 9H); IR (CHCI3) 3280 (br), 3000, 2950, 1600, 1480, 
1460, 1325, 1220, 1165, 1075, 1030, 940, 885, 800, 660 cm-1; EIMS mlz 
(relative intensity) 501 (M+ + 1, 4), 500 (M+, 5), 421 (1), 267 (4), 251 (11), 
204 (51), 189 (53), 173 (36), 91 (47), 43 (100). 
Anal. Cald for C28H40N2O4S: C, 67.16; H, 8.05; N, 5.60. Found: C, 
67.10; H, 8.20; N, 5.71. 
1,4-Dimethoxy-6,7-dihydro-5H-benzocycloheptene (35). n-Buli 
(1.6 M in hexanes, 3.9 mL, 3.00 mmol) was added to a cold (-65 °C) solution 
of 34 (3.00 g, 5.99 mmol) in THF (40 mL). After the reaction mixture was 
stirred at this temperature for 15 min, the cold bath was removed and the 
mixture was stirred at room temperature for another 15 min, after which the 
mixture was poured into sat. NH4CI (20 mL). The layers were separated, the 
aq. layer was extracted with ether (2x15 mL), and the combined organic 
extracts were worked up. Purification by PCTLC (EtOAc-hexanes 1:4) 
afforded 35 as a clear yellow liquid (1.19 g, 98%). UV (CH3CN), Xmax (e) 206 
(16 880), 225 (7 230, sh), 289 (2 610) nm; IR (neat) 3000, 2910, 2880, 2810, 
1590 (vw), 1480, 1255, 1220. 1205, 1080, 790, 715 cm-1; 1H NMR (500 
MHz, CDCI3) 8 6.712-6.667 (m, 2H), 5.727-5.705 (m, 1H), 5.520-5.495 (m, 
1H), 3.771 (s, 3H), 3.756 (s, 3H), 3.528-3.513 (br m, 2H), 3.118-3.093 (m, 
2H), 2.288-2.276 (br m, 2H); EIMS mlz (relative intensity) 205 (M+ + 1, 14), 
204 (M+, 100), 189 (47), 174 (19), 129 (20), 115 (28), 91 (31). 
Anal. Calcd for C i 3 H 1 8 0 2 : C, 76.44; H, 7.90. Found: C, 76.37; H, 8.00. 
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1 , 4 - D i m e t h o x y - 8 , 9 - d i h y d r o - 5 H - b e n z o c y c l o h e p t e n e (36). 
Rhodium trichloride trihydrate (10 mg) was added to a solution of diene 35 
(1.00 g, 4.90 mmol) in CHCI 3 -EtOH (1:1, 30 mL) and the reaction mixture 
was heated at reflux for 8 h. After the mixture cooled, it was diluted with 
water (75 mL), extracted with CH2CI2 (3 x 15 mL), and worked up. 
Purification by PCTLC (EtOAc-hexane 1:4) afforded 36 as a clear yellow 
liquid in quantitative yield. UV (CH3CN), Xmax (e) 209 (22 550), 255 (8 310), 
312 (3 980) nm; IR (neat) 3020, 2920, 2820, 1590, 1470, 1250, 1210.1080, 
780, 710 cm-1; NMR (500 MHz. CDCI3) 8 6.768 (app. t. J - 1.4 Hz, 1H), 
6.735 (d, J - 9.0 Hz, 1H), 6.665 (d, J - 9.0 Hz, 1H), 6.125-6.080 (m, 1H), 
3.793 (S, 3H), 3.780 (s, 3H), 2.793-2.769 (m, 2H), 2.262-2.220 (m, 2H), 
2.033-1.981 (m, 2H); EIMS mlz (relative intensity) 205 (M+ + 1,16), 204 (M+, 
100), 189 (53), 174 (21), 129 (26), 115 (33), 91 (34). 
Anal. Calcd for C13H18O2: C, 76.44; H, 7.90. Found: C. 76.32; H, 8.18. 
1,4-Dimethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ol 
(37). Alkene 36 (514.7 mg, 2.52 mmol) was dissolved in dry C H 2 C I 2 (20 
mL), and the resulting solution was cooled to 0 °C. A solution of freshly 
prepared dimethyldioxirane in acetone (1.1 eq, ca 0.1 M) was added 
dropwise. The reaction mixture was stirred at this temperature for 1 h. Then, 
the solution was dried over Na2SC-4 and concentrated under reduced 
pressure to afford a light yellow solid. The crude product was dissolved in 
anhydrous THF (20 mL) and added to a cold (0 °C) suspension of LAH in 
THF (1M solution, 2.77 mL, 2.77 mmol) under Ar. The mixture was stirred at 
this temperature for 15 min and then allowed to warm to room temperature 
with continued stirring for 5 h. The mixture was cooled to 0 °C and quenched 
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with a sat. Na+/K+ tartrate solution. When the solids turned completely white, 
the mixture was filtered through a silica gel plug, washed with ether (3x15 
mL), and the filtrate was worked up. Purification by MPLC (EtOAc-hexanes 
1:4) afforded 37 as a white solid (499.7 mg, 89% overall). Analytical sample 
was obtained by recrystallization from CH2CI2-hexanes: mp 100-101 °C; UV 
(CH3CN), Xmax (c) 204 (28 300), 226 (7 375, sh), 289 (3 165) nm; IR (CHCI3) 
3600 (sharp), 3000, 2920, 1595,1480,1245,1215, 1090, 795 cm-l; 1H NMR 
(500 MHz, CDCI3) 6 6.693 (d, J • 8.9 Hz, 1H), 6.666 (d, J - 8.9 Hz, 1H), 
3.750 (s, 3H), 3.735 (s,3H), 3.270 ( d, Jm 13.8 Hz, 1H), 3.043 (dd, Jm 14.0, 
8.5 Hz, 1H), 2.950 (dd, J - 13.6, 9.4 Hz, 1H), 2.604 (dd, Jm 13.8,10.7 Hz, 
1H), 2.126-2.039 (br m, 1H), 1.835-1.763 (m, 2H), 1.487 (br s, 1H. D 2 0 
exch.), 1.448-1.397 (m, 2H); EIMS mlz (relative intensity) 223 (M++ 1,17), 
222 (M+, 100), 204 (9), 189 (29), 178 (31), 151 (37), 121 (34), 105 (34), 91 
(52). 
Anal. Calcd for C13H18O3: C, 70.24; H, 8.16. Found: C. 70.00; H, 8.10. 
1,4-Dimethoxy-5,7,8,9-tetrahydro-6H-benzocyclohepten-6-
one (38). To a suspension of PCC (252.1 mg, 1.17 mmol) in C H 2 C I 2 (20 
mL) was added dropwise a solution of 37 in C H 2 C I 2 (5 mL) at room 
temperature. The mixture was stirred at this temperature for 1.5 h. Then, it 
was filtered through a silica gel plug and the gummy residue was washed 
thoroughly with C H 2 C I 2 (2 x 15 mL) and EtOAc ( 3 x 1 5 mL). Evaporation 
afforded a pale yellow solid which was purified by PCTLC (EtOAc-hexanes 
1:2) to afford 38 as a white solid (114.0 mg, 89%); mp 87-87.5 °C; UV 
(CH3CN), Xmax (e) 206 (25 010), 292 (3 500) nm; IR (CHCI3) 3000. 2930, 
1700,1480,1200,1160.1090 cnr*; 1H NMR (500 MHz. CDCI3) 6 6.760 (d, J 
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= 9.0 Hz, 1H), 6.711 (d, J - 8.9 Hz, 1H), 3.773 (s, 2H), 3.766 (s, 3H), 3.756 (s, 
3H), 2.927 (t, J m 6.7 Hz, 2H), 2.467 (t, J - 7.0 Hz, 2H), 1.932 (quintet, J m 7.0 
Hz, 2H); EIMS mlz (relative intensity) 221 (M++ 1,11), 220 (M+, 100), 191 
(14), 177 (34), 165 (76), 149 (35), 105 (21), 91 (30). 
Anal. Calcd for C13H16O3: C, 70.89; H, 7.32. Found: C, 70.82; H, 7.29. 
5 , 8 - D i m e t h o x y - 1 , 2 - d i h y d r o n a p h t h a l e n e (40). Rhodium 
trichloride trihydrate (100 mg) was added to a solution of 39 (21.90 g, 0.115 
mol) in CHCl3-EtOH (1:1, 200 mL) and the mixture was refluxed overnight. 
During this time, the mixture turned black. Purification by column 
chromatography (EtOAc-hexanes 1:4) after usual work up afforded 40 as a 
white solid (20.63 g, 94%): mp 62-62.5 °C; UV (CH3CN), Xmax (e) 211 (19 
400), 214 (19 225). 268 (7 400), 283 (3 920, sh), 317 (4 165) nm; IR (CHCI3) 
3010, 2940, 1595, 1480, 1345, 1255. 1100, 950 cnr 1 ; *H NMR (500 MHz, 
CDCI3) 6 6.793 (dt. J = 10.0, 2.0 Hz, 1H), 6.661 (q, J • 9.0 Hz, 2H), 6.048-
6.010 (m, 1H), 3.769 (s, 6H), 2.743 (t, J m 8.6 Hz, 2H), 2.260-2.214 (br m, 
2H); EIMS mlz (relative intensity) 191 (M+ + 1, 14), 190 (M+, 100), 175 (61), 
159 (34), 144 (20). 131 (14), 115 (74), 91 (19). 
Anal. Calcd for C12H14O2: C, 75.76; H, 7.42. Found: C, 75.48; H, 7.60. 
5,8-Dimethoxy-1,2,3,4-tetrahydronaphthalen-1-ol (41). To a 
cold solution (ice bath temperature) of 40 (10.92 g, 57.4 mmol) in THF (75 
mL) was added slowly via syringe 57.4 mL of borane-THF complex (1M 
solution). The reaction mixture was stirred at this temperature for 15 min and 
at room temperature for 36 h. After this time, the mixture was cooled down 
(ice bath temperature) and water (60 mL) was added dropwise, followed by 
a solution of 3M NaOH (48 mL) and 30% H 2 0 2 (24 mL). The ice bath was 
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removed and the mixture was stirred at room temperature for 1 h. Then, the 
mixture was diluted with brine and extracted with ether (3 x 50 mL). The 
combined organic extracts were worked up. Purification by MPLC (EtOAc-
hexanes 1:4) afforded 41 as a white solid (9.24 g, 77%): mp 62-63 °C (lit. 1 3 9 
65 °C). Spectroscopic data agree with reported values. 1 3 9 
5,8-Dimethoxy-1-tetralone (42). To a suspension of PCC (8.70 g, 
40.4 mmol) in CH2CI2 (25 mL) was added dropwise a solution of 41 (4.20 g, 
20.2 mmol) in CH2CI2 (10 mL). The mixture was stirred at room temperature 
for 1 h, then diluted with CH2CI2 (15 mL), filtered through a silica gel plug, 
and concentrated under reduced pressure. Purification by MPLC 
(EtOAc-hexanes 1:2) afforded 42 as a yellowish white solid (3.60 g, 87%): 
mp 59.5-60 °C (lit. 1 3 9 60-62 °C; lit. 1 6 6 58-62 °C). Spectroscopic data agree 
with reported va lues . 1 3 9 , 1 6 6 
1 ,4-Dimethoxy-5,7,8 ,9 -tetrahydro-6H-benzocyclohepten-6-
one (38). A slurry of 50% NaH (609.5 mg, 12.7 mmol) in dry DMSO (40 mL) 
was stirred at room temperature for 1 h or until the NaH was completely 
dissolved. Methyltriphenylphosphonium bromide (4.52 g, 12.7 mmol) was 
added in portions over a period of 5 min and the mixture was stirred for an 
hour. After this time, ketone 42 (1.31 g, 6.33 mmol) was added in one 
portion. After 2 h of stirring, the mixture was poured into ice-water (100 mL). 
The aqueous phase was extracted with ether (3 x 50 mL) and the combined 
organic extracts were worked up to afford a yellow solid. The crude product 
was dissolved in MeOH (25 mL) and added in one portion to a freshly 
prepared solution of thallium (III) nitrate trihydrate (4.74 g, 10.7 mmol) in 
MeOH (30 mL). The mixture was stirred vigorously for 1 min and CHCI3 (100 
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mL) was added. The mixture was filtered, washed with brine, and worked up. 
Purification by MPLC (EtOAc-hexanes 1:2) afforded 38 as a white solid 
(1.043 g, 75% overall). Spectroscopic data agree with those of the 
compound obtained by the keto transposition. 
1,4-Dimethoxy-6-(2-trimethylsllyl)ethynyl-6,7,8,9-tetrahydro-
5H-benzocyclohepten-6-ol (43). Anhydrous CeCl3 (942.1 mg, 3.82 
mmol) was dried in vacuo at 140 °C for 1 h with stirring. After cooling to room 
temperature, it was suspended in THF (10 mL) and stirred overnight at this 
temperature under Ar. A solution of (2-trimethyl-silyl)ethynyl lithium, 
prepared by adding n-BuLi (1.56/W in hexanes, 2.1 mL, 3.28 mmol) to a 
solution of trimethylsilylacetylene (398.6 mg, 4.06 mmol) in THF (10 mL) at 
-78 °C, was added to the suspension of CeCl3 at -78 °C. The white mixture 
was stirred at this temperature for 1 h. Ketone 38 (400.0 mg, 1.82 mmol) was 
added in one portion and the reaction mixture was stirred at -78 °C for 1 h 
and at room temperature for 2 h. Then the reaction mixture was quenched 
with sat. NH4CI (30 mL), diluted with ether (50 mL) and the organic layer 
was washed with brine (2 x 25 mL), and worked-up. Purification by column 
chromatography (EtOAc-hexanes 1:2) afforded 43 in quantitative yield (580 
mg): mp 66-67 °C, UV (EtOH), W (e) 204 (30 605), 226 (7 125. sh), 291 (3 
140) nm; IR (CHCI3) 3580 (sharp), 3000, 2930, 2820, 2160, 1590, 1480. 
1250. 1100, 860. 840 cnrr1; 1 H NMR (500 MHz. CDCI3) 8 6.703 (d, J • 8.9 
Hz, 1H), 6.654 (d, J = 8.9 Hz, 1H), 3.761 (s, 3H), 3.732 (s, 3H), 3.426 (d, J = 
13.9 Hz, 1H), 3.135 (d, J - 13.4 Hz, 1H), 3.064 (brt, J - 12 Hz, 1H), 2.576 (br 
t, J - 11.5 Hz, 1H), 2.152-2.110 (m, 1H), 2.044 (s, 1H, D 2 0 exch.), 
2.205-1.961 (m, 1H), 1.774 (br s, 1H), 1.553 (br s, 1H); EIMS mlz (relative 
70 
intensity) 319 (M+ + 1, 15), 318 (M+, 66), 301 (10), 178 (100), 165 (32), 105 
(15), 91 (24). 
Anal. Calcd for Ci8H 2e0 3Si: C, 67.88; H, 8.23. Found: C, 67.49; H, 8.60. 
6-Acetyl-1,4-dimethoxy-6,7,8,9-tetrahydro-5H-benzocyclo-
hepten-6-ol (44). A solution of 43 (1.31 g, 4.11 mmol) in THF (20 mL) 
was added dropwise to a solution of yellow HgO (240.4 mg, 1.11 mmol) in 
3M H2SO4 (12 mL). The mixture was stirred at room temperature in the dark 
under Ar for 2h. Then, the mixture was diluted with H 2 0 (50 mL), extracted 
with C H 2 C I 2 (3 x 75 mL), and the combined organic layers were washed 
with brine (30 mL) and worked-up. Purification by MPLC (EtOAc-hexanes 
1:2) afforded 44 as a yellowish white solid (942.9 mg, 87%): mp 91.5-92 °C; 
UV (EtOH), Xmax (e) 204 (26 355), 226 (7 280, sh), 291 (3 185) nm; IR 
(CHCI3) 3580 (sharp), 3000, 2940, 2830, 1700, 1590 (vw), 1480, 1255, 
1100, 900 cm- 1 ; 1 H NMR (500 MHz, CDCI3) 5 6.737 (d, J - 8.9 Hz, 1H), 
6.691 (d, J = 8.9 Hz, 1H), 3.752 (s, 3H), 3.724 (s, 3H), 3.337 (ddd, J = 14.4, 
7.8, 2.6 Hz. 1H), 3.294 (dd, J m 14.2, 1.2 Hz, 1H), 3.104 (s, 1H, D 2 0 exch.), 
2.968 (d, J » 14.2 Hz, 1H), 2.531 (ddd, J « 14.2, 9.8, 2.6 Hz, 1H), 1.977-1.915 
(m, 1H), 1.848-1.810 (m, 1H), 1.680-1.617 (m, 2H); EIMS mlz (relative 
intensity) 265 (M++ 1, 7), 264 (M+, 38), 222 (13), 221 (60), 204 (15), 203 
(98), 191 (32), 177 (25), 161 (33), 121 (23), 91 (36), 77 (25). 44 (100). 
Anal. Calcd for Ci5H 2 o0 4 : C, 68.16; H, 7.63. Found: C, 68.00; H, 8.00. 
4 -Demethoxy -7 -deoxy -8a-homodaunomycinone (45). A n 
intimate mixture of 44 (2.10 g, 7.94 mmol), phthalic anhydride (3.53 g, 23.8 
mmol), AICI3 (23.31 g, 174.8 mmol), and NaCI (5.11 g, 87.4 mmol) was 
placed in a beaker and immersed in a sand bath pre-heated at 180-182 °C. 
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The mixture became a dark red melt in approximately 1 min and it was 
stirred continuously with a glass rod for another 6 min. After the reaction 
mixture was allowed to cool, a sat. aq. solution of oxalic acid (150 mL) was 
added and the red aq. solution was poured into an Erlenmeyer. CHCI3 (250 
mL) was added and the resulting mixture was stirred until the aqueous layer 
became pale yellow. The organic layer was separated and filtered through a 
celite plug. TLC (EtOAc-hexanes 1:2) indicated the presence of the product 
and baseline impurities. Concentration and recrystallization from CHCI3 
gave 45 as a red-orange solid (2.47 g, 85%): mp 223-224 °C; UV (EtOH), 
Xmax (e) 204 (25 310), 228 (14 005, sh), 253 (40 255), 257 (40 835), 292 (8 
070) nm; IR (CHCI3) 3590 (sharp), 2930, 2850. 2360, 1700, 1620. 1585, 
1455, 1400, 1370. 1340. 1260, 970 cnrr 1 ; lH NMR (500 MHz, CDCI3) 8 
13.706 (s, 1H, D 2 0 exch.), 13.465 (s, 1H, D 2 0 exch.), 8.345-8.308 (m, 2H), 
7.819-7.801 (m, 2H), 4.147 (br s, 1H, D 2 0 exch.), 3.629 (app. dd, J = 14.2, 
6.1 Hz, 1H), 3.533 (dd, J • 14.1, 1.4 Hz, 1H), 3.032 (d, J « 14.0 Hz, 1H), 
2.619-2.563 (m, 2H), 2.364 (s, 3H), 2.103-2.041 (m, 1H), 1.780-1.732 (m, 
1H); EIMS mlz (relative intensity) 366 (M+ 10), 323 (17), 305 (2), 268 (13), 
167 (5), 149 (59), 91 (16), 43 (100). 
Anal. Calcd for C 2 iHia06: C, 68.84; H, 4.95. Found: C, 68.68; H, 5.01. 
4-Demethoxy-7-deoxy-6,12-diacetyl -8a-homodaunomycinone 
ketal (46). A mixture of ketone 45 (105.0 mg, 0.287 mmol), ethyleneglycol 
(355.8 mg, 5.73 mmol), and pTsOH (10 mg) in dry benzene (25 mL) was 
heated to reflux under Ar for 12 h with azeotropic removal of H 2 0 
(Dean-Stark apparatus). The reaction mixture was allowed to cool and the 
benzene was decanted. The red solid was dissolved in pyridine (8 mL) and 
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acetic anhydride (1.05 g, 10.3 mmol) and DMAP (2-3 mg) were added to the 
solution. The mixture was stirred for 19 h at room temperature under Ar. 
Then the solution was concentrated under high vacuum and the 
brownish-yellow solid obtained was purified by MPLC (EtOAc-hexanes 1:2) 
to afford 46 as a yellow solid (127.9 mg, 90% overall): mp 252 °C dec; UV 
(EtOH), Xmax (e) 209 (27 920), 238 (14 715, sh), 260 (43 700), 281 (11 460, 
sh), 346 (6 015) nm; IR (CHCI 3) 3580 (sharp), 2990, 1770, 1670, 1590, 
1570, 1450, 1360, 1330, 1280, 1250, 1180. 1100, 970, 950 cm*1; NMR 
(500 MHz, CDCI3) 6 8.134-8.109 (m, 2H), 7.710-7.690 (m, 2H), 4.030 (s, 4H), 
3.575 (d, J m 14.0 Hz, 1H), 3.223 (dd. J = 14.1, 6.6 Hz, 1H), 2.810 (d. J * 14.2 
Hz, 1H), 2.556 (s, 3H), 2.513 (s, 3H), 2.290 (dt, J = 5.8, 1.5 Hz, 1H), 2.166-
2.114 (brm, 1H), 1.885-1.822 (brm, 1H), 1.754 (app. t, J =8.4 Hz, 1H), 1.357 
(s, 3H); CIMS (NH 3) m/z (relative intensity) 512 (M+ + 18, 30), 495 (M++ 1, 
4), 453 (3), 435 (100), 99 (58), 87 (22), 43 (16). 
Anal. Calcd for C27H26O9I/2H2O: C, 64.40; H, 5.41. Found: C, 64.20; H, 
5.40. 
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Part II 
Biosynthesis of Coloradocin. Origin of the Carbons 
A. Introduction 
The macrolide antibiotic coloradocin (luminamicin, 1) is an 
antianaerobic antibiotic which was first reported by Omura and co-workers1 
in 1985 by isolation from a fermentation broth of soil microorganisms 
belonging to the genus Nocardiodes. In 1987, Jackson and co-workers2 
reported finding it in a new species of Actinoplanes, designated 
Actinoplanes coloradoensis. 
Coloradocin has good to moderate activity against a broad range of 
anaerobic organisms, such as Clostridium sp. and Bacteroides sp. It is most 
potent against microaerophilic bacteria, such as Neisseria gonorrhoeae and 
Haemophilus influenzae, including ampicillin-resistant strains. Coloradocin 
does not inhibit most aerobic microorganisms. 
The stereochemical details of the structure of coloradocin have not been 
elucidated. The carbon framework, however, has been established3 and 
reveals an unusual octahydronaphthalene moiety apparently related to a 
small family of antibiotics comprising the nargenicins4 and nodusmicins (2).5 
Distinctive structural features of coloradocin, including a) the different 
placement of the oxygen bridge across the octalin ring system in comparison 
with nargenicin and nodusmicin; b) the presence of the maleic anhydride 
moiety, quite rare in natural products; and c) the non-apparent biosynthetic 
origin of the second carbon chain forming the 14-membered oxamacrolide 
ring, prompted us to pursue a biosynthetic study of this antibiotic. 
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B. Biosynthetic Origin of the Carbon Skeleton of 
Nargenicin and Nodusmicin 
The macroiide ring of nargenicin and nodusmicin is derived from the 
typical Actinomycete acetate-propionate pathway,6*7 which incorporates four 
propionate and five acetate units. This pathway involves an intramolecular 
Diels-Alder reaction at a late stage of the biosynthesis8* 9 (Scheme 1). 
Chlorothricin, 1 0 - 1 2 kijanimicin,13 and tetrocarcin14 are other examples of 
natural products that exhibit an intramolecular Diels-Alder reaction in their 
biosyntheses, a process necessary for the construction of the octalin ring 
system. This Diels-Alder reaction is believed to be a nonenzymic-catalyzed 
process. It was also found that the S-methyl of methionine labeled the 
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O-methyl carbon of these antibiotics. Furthermore, molecular oxygen was 
found to be the biosynthetic source of the 2,18 and 8-13 bridge oxygens.8 
Biosynthetic Origin of Nargenicin and Nodusmicin 
L- Methionine m«1hyt "C 
R - H Nodusmicin7 
R - ^ c - ^ Nargenicin7'8 6 H 
Scheme 1 
C. NMR Studies of Coloradocin 
Prior to the biosynthetic studies of coloradocin, structure proof and 
essential elements of the structure were confirmed using 1 H - , 1 3 C - , and 2D 
NMR techniques. Structure proof was relevant and mandatory for the correct 
interpretation of the results. If the structure proposed by McAlpine and 
co-workers 3 had been wrong, this would have led us, consequently, to a 
wrong biosynthetic derivation. Furthermore, the results from the feeding 
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experiments would have been inconsistent with the proposed derivation and 
lack any logical significance. 
From a structural point of view, we were concerned about the point of 
attachment of the minor carbon chain to the major chain, that is, whether or 
not the molecule is tethered as proposed by McAlpine and co-workers. We 
were also concerned about the possibility of solvent induced chemical shift 
(SICS) when the NMR solvent was changed from DMSO-de (used by 
McAlpine) to CD 2 CI 2 (used in our NMR studies); therefore, all 1 3C-signals 
were re-assigned using CD2CI2 as solvent. 
Figures 1 and 2 show 1 H - (300 MHz) and 1 3 C NMRs (125 MHz) of 
coloradocin. In these spectra, most signals are well resolved and separated, 
facilitating proper assignment and correlation, with the exception of C17 and 
C19, C4 and C12, and C3 and C25. 
Simple inspection of the 1 H NMR indicated the presence of a polarized 
double bond (protons at 7.86 and 5.65 ppm), and other protons on 
unsaturated centers as well (5.44 to 6.06 ppm). Resonances from 3.27 to 
4.90 ppm indicated the presence of several protons on carbons bearing 
oxygen. The resonance at 3.27 ppm was indicative of a methoxy group. 
Protons on saturated carbons resonated from 0.99 to 2.87 ppm. Two methyl 
groups were found in this area: one at 0.99 ppm and the other at 1.75. 
A 1 H - 1 3 C correlation spectrum (500 MHz) in CD2CI2 (Figure 3) helped us 
with the assignment of each proton to its carbon. The assignment was 
facilitated by running a DEPT 1 3 C NMR experiment (result not shown) which 
revealed the carbon multiplicities. 
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This correlation experiment also helped us to solve the problem related 
to SICS. All 1 3 C NMR assignments were identical to those obtained in 
DMSO-d6, with the exception of C11 and C13 that were reversed: DMSO-d6: 
C11, 75.3 ppm; C13, 75.9 ppm. In CD 2 CI 2 : C11, 77.7 ppm; C13, 76.8 ppm. 
The results from a long-range 1 H - 1 3 C correlation NMR (FUCOP, Figure 
4) in conjunction with those of the 1 H - 1 3 C correlation NMR spectrum 
provided enough evidence to build a partial structure for coloradocin. The 
complete structure of this molecule was obtained after examination of the IR 
spectrum (not shown). The spectrum indicated the presence of two bands at 
1835 cm*1 (weak) and 1760 cm*1 (strong), due to symmetrical and 
antisymmetrical stretching frequencies, respectively, of a substituted maleic 
anhydride functionality. 
The FUCOP experiment showed long-range correlation between C29 
and H31 and also between C28 and H26. These findings allowed us to 
formulate a structure in which the olefinic anhydride carbons were 
connected to carbons 26 and 31. 
The attachment of the minor carbon chain to the major one was 
indicated by a long-range correlation between H32 and C19. Unfortunately, 
no long-range correlation was seen between H22 and C24. Examining 
regions deeper in the contour plot increased the noise level such that it was 
difficult to differentiate signal from noise. 
A 1 H - 1 H correlation (90-90 COSY) spectrum was also run to verify 
proton connectivity. 1 H- 1 H Connectivities are shown on the spectrum (Figure 
5). No discrepancies in the signals were found from those obtained by 
McAlpine and co-workers. 
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1 H NMR Spectrum of Coloradocin (300 MHz) 
13c NMR Spectrum of Coloradocin (125 MHz) 
H - 1 3 C Correlation Spectrum of Coloradocin 
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Long-Range 1 H - 1 3 C Correlation Spectrum of Coloradocin 
Figure 4 
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Figure 5 
95 
2D INADEQUATE NMR Spectrum of 
Double Labeled Coloradocin 
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Once we confirmed the structure proposed, we proceeded with the 
feeding experiments using 13C-labeled precursors. 
Further evidence of the carbon skeleton connectivity was obtained by 
running a 2D INADEQUATE experiment of coloradocin obtained from the 
[2-1 3C]-acetate labeling experiment (Figure 6). See details in Results and 
Discussion section. 
D. Fermentation of Actinoplanes coloradoensis and 
Incorporation of 1 3 C -Labeled Precursors 
Fermentation experiments and incorporation of labeled precursors were 
done at Abbott Laboratories according to Dr. Jackson's procedure described 
in reference 2 (see Experimental Section for details). Because of the slow 
growth of the microorganism, a complex medium was necessary to assure 
full development and antibiotic production. The medium contained energy 
sources, such as glucose for rapid growth, and starch to sustain the growth 
of the microorganism. Amino acids were added in the form of partially 
digested peptides (peptone) and amino acid mixtures (NZ amine). Yeast 
extract provided the co-factors necessary for the biochemical 
transformations. Ions necessary as catalysts for the biochemical reactions 
were administered as salts. 
Coloradocin was produced by submerged fermentations of A. 
coloradoensis. The precursors were administered to second passage seed 
on days 3, 4, and 5 according to Table 1. The fermentation was harvested on 
day 6 and the pH adjusted to 4. The precursors were added in portions to 
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avoid an overload of the Kreb's cycle, in that way, the precursors were not 
used as energy source and their utilization in secondary metabolism was 
assured. 
The antibiotic was extracted by passage over a column of XAD-2 resin, 
which was rinsed well with water and stripped with methanol. The crude 
material was purified by reabsorption onto XAD-2 and elution with a gradient 
from water to methanol. Coloradocin-containing fractions were combined 
and purified by chromatography on low pressure columns of C18 RP silica 
gel in CH 3 CN-H 2 0 to obtain spectroscopic^ ly pure coloradocin (Scheme 2). 
The resulting labeled samples were analyzed by 125 MHz 1 3 C NMR. 
The general instability of coloradocin in hydroxylic solvents was 
demonstrated by its loss of activity upon exposure to hydroxide ion and also 
by changes in its 1 H NMR spectrum after standing in MeOH. This instability 
made the isolation procedure cumbersome because the crude material had 
to be worked quickly and carefully to avoid decomposition. The fact that 
coloradocin was isolated in small amounts also made its isolation 
formidable. 
Table 1 
Substrate Addition 
sodium [1-13C]-acetate 
sodium [2-13C]-acetate 
0.02% 
0.02% 
sodium [1,2-13C2]-acetate 
sodium [1-13CJ-propionate 
L-[mefny/-13C]-methionine 
sodium [2,3-13C2]-succinate 
0.02% 
0.01% 
0.01% 
0.007% 
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L-[1-13C]-glutamic acid 
[3-13C]-oxaloacetic acid 
0.003% 
0.003% 
Isolation of Labeled Coloradocin 
Broth 
Amberiite XAD-2 
Dark Brown Oil 
2 x Sephadex LH-20 (MeOH) 
Brown Bioactive Solid 
2 x MPLC Sepralyte" C-18 silica gel (CH3CN:H20 1:1) 
Coloradocin (90%) 
(Suitable for 1 3 C NMR) 
Semi-Preparative HPLC 
Coloradocin (99%) 
Scheme 2 
E. Results and Discussion 
Enrichment for single labeled substrates were calculated by comparing 
peak heights of labeled samples relative to that of the same carbon from 
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unlabeled coloradocin spectrum measured under identical parameters. The 
relative peak heights for experiments with substrates other than methionine 
were normalized to the ratio of the C23 signals at 58.2 ppm. For double 
labeled substrates, the enrichment was presented as the ratio of the sum of 
the peak height of the satellites to the height of the center peak. 
In principle, the major macrolide ring could be derived from the typical 
Actinomycete acetate-propionate pathway or from the acetate-methionine 
pathway of fungi. The oxygens at C11, C13, and C17 are appropiately 
placed for either pattern. 
Major carbon chain. Acetate Feeding. The results (Table 2), which 
were fully in accord with a polyketide derivation for the major carbon chain 
portion of coloradocin, showed that carbons 1, 3, 5, 7, and 11 were derived 
from C-1 of acetate and that carbons 2, 4, 6, 8, and 12 from C-2 of acetate 
(Figure 7). The results with respect to the minor carbon chain will be 
discussed later. 
Those carbons directly derived from acetate showed a relative 
enrichment of approximately 3-4 fold. It is noteworthy that incorporation of 
[ 1 - 1 3 C j - and [2- 1 3C]-acetate led to secondary enrichment of 
propionate-derived carbons (see Table 2 and 2D INADEQUATE spectrum of 
[2- 1 3 C]-acetate labeled coloradocin, Figure 6). These secondary 
enrichments were approximately 2 fold, and these carbons are starred in the 
table. This enrichment pattern indicates an active tricarboxylic acid (TCA) 
cycle, 1 5 which transforms acetate to succinate, which then is converted into 
methylmalonate (and propionate) by an active methylmalonyl-CoA mutase 
(Figure 8 ) . 1 6 This interpretation is supported by the high number of 
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secondary enrichments obtained from the succinate feeding experiment 
(Table 3). To avoid this excess intramolecular multiple labeling effect, 
unlabeled propionate was added to the medium. This is different from the 
procedure of Cane and co-workers,8 which added the corresponding 
unlabeled acetate and propionate precursors. 
Our strategy was based on the equilibrium of the biotransformation of 
acetyl-CoA to propionyl-CoA. Being the latter at one end of the process, it 
was obvious that adding unlabeled propionate would shift the equilibrium 
process to its other end (acetyl-CoA), and this shift in the equilibrium would 
diminish the excess intramolecular multiple effect. 
The incorporation experiment using [1-13C]-propionate, on the other 
hand, did not result in the enrichment of carbons originating from [1- 1 3C]- nor 
[2-13C]-acetate. We postulate that this is due to acetyl-CoA being found in 
much higher concentration in the cells (bigger pool) than propionyl-CoA; 
therefore, addition of more propionate does shift the equilibrium to the 
acetyl-CoA end, but the dilution factor brings this to a barely detectable 
incorporation level. 
Table 2. 1 3 C Enrichment of Coloradocin Carbons bv Precursors 
enrichment 
[1-13CJ- [ 2 - 1 3 q - [1,2-13C2]- [1--<3C]-
carbon acetate acetate acetate propionate 
1 4.1 1.3 1.4 
2 1.0 4.3 1.4 1.2 
3 4.5 1.1 1.1 1.1 
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4 1.1 3.7 1.1 1.0 
5 4.5 1.1 1.0 1.0 
6 1.0 3.7 1.0 1.0 
7 3.6 1.0 1.0 1.2 
8 1.2 3.9 1.0 1.0 
9 1.8* 0.9 0.4 6.9 
10 1.1 1.6* 0.4 1.0 
11 4.5 1.1 0.6 1.2 
12 1.0 3.7 0.6 1.0 
13 1.7* 0.8 0.2 5.7 
14 0.9 1.2* 0.2 1.0 
15 2.7* 1.0 0.2 5.8 
16 1.3* 1.1 0.2 1.1 
17 2.0* 1.2* 0.2 4.9 
18 1.4* 1.1 0.2 0.9 
19 2.0* 1.1 4.9 
20 1.0 1.0 1.2 
21 1.0 1.1 0.9 
22 1.4* 1.1 1.1 
23 1.0 1.0 1.0 
24 4.2 1.3 2.2 0.8 
25 1.3 3.3 2.2 0.8 
26 1.2 1.7 1.0 
27 1.0 1.9 0.6 1.2 
28 1.9 1.2 0.6 2.1 
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29 2.5 0.9 0.6 
30 0.9 1.1 0.6 1.0 
31 1.1 1.2 0.9 1.2 
32 3.9 0.9 0.9 0.9 
* secondary enrichment. 
Incorporation of [1 - C]- and [2- J C] -Acetate 
( ) Secondary enrichment 
Figure 7 
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Biotransformation of Acetate to Propionate 
Acetyl -CoA 
TCA 
Succinyl -CoA 
Methylmalonyl-CoA mutase 
L-Methylmalonyl-CoA 
Methylmalonyl eplmerase 
D-Methylmalonyl-CoA 
Proplonyi -CoA carboxylase 
Propionyl -CoA 
Figure 8 
Propionate Feeding. The [1-13C]-propionate experiment (Table 2, 
Figure 9) enriched carbons 9, 13, 15, 17-19 (poorly resolved in CD2CI2). 
These carbons showed relative enrichment of 5-7 fold. This relative 
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enrichment is consistent with a smaller supply of propionate in the medium 
and a smaller pool in the microorganism. 
These results, in conjunction with those obtained from the 
acetate-labeling experiments, indicated that the major carbon chain of 
coloradocin is of polyketide origin. It is derived from five acetate and four 
propionate units. This incorporation pattern is analogous to that of the 
nargenicin/nodusmicin antibiotics. 
Methionine Feeding. The L-[mefny/-13C]-methionine experiment 
indicated that only the O-methyl carbon of the major carbon chain showed 
enrichment (greater than 15 fold). This experiment also proved that the 
major carbon chain was not derived from the acetate-methionine pathway. 
Incorporation of [1- 3C]-Propionate 
C H 3 O 
23 
Figure 9 
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Double Labeled Feeding. The incorporation results (Table 2) and a 
double quantum filtered INADEQUATE experiment of coloradocin obtained 
from the [1,2-13C2]-acetate feeding experiment (conducted at Abbott Labs.) 
showed intact incorporation of acetate and a realtive enrichment of 2-10 fold 
higher than those obtained by secondary enrichment. 
Summary. The conducted experiments accounted for the bioorigin of 
all the carbons of the major carbon chain and there were no unexpected 
results. 
Minor carbon chain. With the fundamental precursors of the major 
carbon chain firmly established, we directed our efforts to the determination 
of the biosynthetic origin of the minor carbon chain. 
Derivation analysis (Scheme 3) of the minor carbon chain indicated that 
a polyketide pathway was not apparent. Various alternatives were plausible, 
including acetate or acetate via succinate, methionine, and succinate. 
Minor Carbon Chain Derivation 
acetate y 
via succinate 0 methionine 
succinate 
or acetate 
succinate 
Scheme 3 
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Acetate Feeding. The [1-1 3C]-acetate experiment indicated that 
carbons 24, 28, 29, and 32 were enriched, whereas carbons 25, 26, and 27 
were enriched when [2-13C]-acetate was the precursor (Table 2, Figure 10). 
The former experiment showed relative enrichment of 3-4 fold, and the latter, 
of 1.5-3 fold. Incorporation results (Figure 10) and a double quantum filtered 
INADEQUATE experiment of coloradocin obtained from the 
[l,2-1 3C2]-acetate feeding experiment (conducted at Abbott Labs.) indicated 
that this label went intact into C24-C25, C27-C28, C29-C30, and C31-C32. 
Altogether, these results indicate that the methyl group of acetate could be 
the biosource for C25, C26, C27, C30, and C31. Surprisingly, these are five 
contiguous carbons. The direction of the acetate incorporation indicates that 
this unit was not derived from the typical Actinomycete acetate-propionate 
pathway. The double labeled experiment confirmed that the C29-C32 
segment was of polyketide origin but via succinate (low incorporation, 
Scheme 4). Carbons 24 and 25 were derived from acetate (polyketide 
origin), and the high relative enrichment, especially in the double labeled 
experiment (10 fold over secondary enrichment), confirmed their derivation. 
The low incorporation of the precursors could indicate that this minor chain 
was synthesized prior to the upper unit and therefore was diluted in the pool 
before coupling. 
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Incorporation of [1 - 1 3 C]- , [2 - 1 3 C]- , and [1,2 - 1 3 C 2 ] -Acetate 
108 
Tricarboxylic Acid Cycle 
Acetyl-CoA 
Scheme 4 
Propionate Feeding. The [1-13C]-propionate experiment (Table 2, 
Figure 11) showed enrichment in C28. The results indicated that the 
C26-C28 segment might be derived from this precursor, but these results 
were not in agreement with the results obtained in the acetate feeeding 
experiments. 
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Incorporation of [1- 1 3 C]-Propionate 
Figure 11 
M e t h i o n i n e Feeding. The next precursor examined for the 
elucidation of the biosynthetic origin of the minor carbon chain was 
L-[mef/iy/-1 3C]-methionine. We proposed that the anhydride moiety could 
come from the oxidation of 2 methyl groups which, in turn, might be derived 
from L-methionine. Feeding experiments indicated that only the O-methyl 
carbon of the major carbon chain showed enrichment, thereby disproving 
this hypothesis. 
A t th is point, we turned our attention to T C A precursors. 
[2,3- 1 3 C 2 ] -Succinate, [3-13C]-oxaloacetate, and L-[1-13C]-glutamate were the 
T C A intermediates used in the experiments that followed. T C A precursors 
were c h o s e n in part because of the low acetate incorporation into the minor 
carbon chain. 
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Table 3. 1 3 C Enrichment of Coloradocin Carbons bv TCA Precursors 
carbon succinate succinate8 glutamate oxaioacetate 
1 1.6* 1.5* 1.1 1.0 
2 1.5* 1.5* 1.1 1.3 
3 3.3* 1.2 1.1 1.2 
4 1.1 1.2 1.1 1.2 
5 1.1 1.3* 1.2 1.2 
6 1.1 1.2 1.1 
CO
 
7 1.3* 2.0* 1.0 1.1 
8 2.3* 1.4* 1.1 1.3 
CD
 1.3* 1.0 1.1 1.2 
10 3.3* 1.3* 1.3 1.2 
11 1.1 1.2 1.0 1.0 
12 1.1 1.2 1.1 1.3 
13 1.1 0.9 1.0 1.1 
14 1.8* 1.3* 1.0 1.2 
15 1.3* 1.1 1.1 1.3 
16 1.9* 1.1 1.1 1.1 
17 1.8* 1.1 1.2 1.3 
18 2.0* 1.0 1.1 1.1 
19 1.8* 1.2 1.2 1.2 
20 2.3* 0.9 1.0 1.2 
21 1.2 0.9 1.1 1.2 
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enrichment 
[2.3-13C2l- [2,3-13C2]- L-[1-13CJ- [3- 1 3C]-
22 3.9* 1.1 1.1 1.3 
23 1.0 1.0 1.0 1.0 
24 0.6 1.1 1.2 1.0 
25 1.0 1.1 1.1 1.2 
26 2.0 1.9 1.1 1.2 
27 1.9 1.7 1.0 1.4 
28 1.2 0.9 1.3 1.0 
29 0.9 0.8 0.9 0.8 
30 0.9 0.8 1.0 1.0 
31 0.9 1.2 1.1 1.2 
32 0.9 
* secondary enrichment 
0.9 1.1 1.0 
8 succinate + unlabeled propionate. 
Succinate Feeding. The [2,3-13C2]-succinate experiment was based 
on the premise that C30 and C27 or the C29-C32 segment might come from 
this precursor. In fact, the results did not support this hypothesis (Table 3). 
Carbons 24, 25, 26, and 27 were the only carbons of the minor carbon chain 
showing enrichment. This finding suggested that C2 and C3 of succinate 
might have been incorporated intact into C26 and C27 (Figure 12). 
Incorporation into C24 and C25 (carbons of acetate origin) was probably 
due to the intramolecular multiple labeling effect (secondary enrichment). To 
avoid this secondary enrichment, unlabeled acetate was added to the 
fermentation medium. Unfortunately, no suppression was obtained (results 
not shown). The secondary enrichment was similar to that obtained without 
the co-substrate. When unlabeled propionate, on the other hand, was added 
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to the medium, excess intramolecular multiple labeling was diminished 
considerably, especially for propionate-derived carbons(see Table 3). These 
results created a great deal of concern. It seemed that succinate was 
transformed to acetate, via TCA, before incorporation. Neither the acetate 
nor the propionate shunting gave support to the succinate hypothesis. It was 
shown that propionate did not exert a back control on succinate. The relative 
enrichments reinforced a succinate bioorigin for C26-C27. 
Glutamate Feeding. The next precursor examined was 
L-[1-13C]-glutamate. it was fed at low levels because of the very high cost of 
this material. The results (Table 3) indicated that it was a very poor substrate 
at low concentration. A possible explanation could be the utilization of 
glutamate in protein biosynthesis, decreasing the bioavailability of this 
precursor for secondary metabolism. The experiment showed enrichment in 
C28, consistent with the incorporation of this unit into the C24-C28 segment. 
The results also showed enrichment in C10 (Figure 13). 
Incorporation of [2 ,3- 1 3 C 2 ] -Succinate Incorporation of L - [ i - 1 3 C] -Giutamate 
FIGURE 1 2 FIGURE 1 3 
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Oxaloacetate Feeding. The feeding experiment with 
[3-13C]-oxaloacetate indicated that this precursor was also a very poor 
substrate. The explanation is similar to that of L-[l-1 3C]-glutamate. Excess 
oxaloacetate could be pulled out of the pool by transaminases, enzymes that 
convert oxaloacetate to aspartate. The latter is needed in protein 
biosynthesis and it is also a precursor for the biosynthesis of asparagine, 
threonine, isoieucine, methionine, and lysine. Excess oxaloacetate beyond 
the amount required in biosyntheses is reduced to malate.17 The experiment 
showed enrichment in carbon 27 (Table 3, Figure 14), consistent with the 
incorporation of C2, C3, and C4 of the oxaloacetate unit into the C26-C28 
segment of coloradocin. Unfortunately, several other carbons of other 
biosynthetic origin (C2, C6, C8, C15, and C22) showed enrichment as well, 
rendering the conclusions hazardous. 
Incorporation of [3- 1 3 C]-Oxaloacetate 
Figure 14 
A plausible explanation for the incorporation of carbons of other 
biosynthetic origin by these TCA precursors could be the high activity of the 
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Kreb's cycle, transforming these TCA intermediates into propionate and/or 
acetate. 
Glucose Feeding. The [U6-13C]-glucose feeding experiment was 
conducted with the hypothesis that C24-C28 and C29-C32 segments might 
be derived from a pentose and a tetrose, respectively. A double quantum 
filtered INADEQUATE experiment of the labeled sample showed 
enrichments in carbons of different bioorigin. This result indicated that the 
labeled glucose was used as an energy source by the microorganism. The 
results were not surprising or unexpected because glucose belongs to a big 
pool and it is not a specific precursor. 
F. Conclusions 
The major carbon chain of coloradocin incorporates five acetate, four 
propionate units and one methionine carbon in a typical Actinomycete 
acetate-propionate pathway. This incorporation pattern is analogous to 
patterns for the nargenicin/nodusmicin antibiotics. 
The minor chain, however, incorporates acetate via an undefined route. 
This fact indicates that the minor chain is not of polyketide origin. Carbons 
24 and 25 are clearly acetate-derived. They may also be derived as part of a 
glutamate residue. Carbon 26 is a mystery unless it comes as part of 
glutamate or succinate. The acetate experiments indicate that the C29-C32 
segment is derived from succinate but a direct feeding experiment failed to 
support this. None of these carbons come from methionine. 
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Based on the results of the glucose experiment, no evidence was found 
for the involvement of the shikimic pathway in the biosynthesis of the minor 
chain. L-Glutamic acid could be the precursor for the C24-C28 segment 
based on the incorporation results. 
We also showed the importance of metabolic shunting when 
co-substrate was added in the feeding experiments to avoid excess 
intramolecular multiple labeling effect, especially when TCA precursors 
were used as substrates. 
Clearly, more experimental work is called for in setting the remaining 
issues raised by this work. 
116 
Experimental 
Feeding experiments were conducted at Abbott Laboratories by Dr. 
Marianna Jackson and co-workers. 1 3 C NMR and 2D INADEQUATE 
experiments of the [1,2-13C2]-acetate labeling experiment were run at Abbott 
Laboratories. NMR spectra were obtained with either a General Electric GN 
300 or GN 500 spectrometer using 5mm probes. 
Organism 
Actinoplanes coloradoensis sp. nov. strain AB 921J-26 was used for this 
work. 
Fermentation 
The fermentation medium consisted of glucose monohydrate 1%, starch 
(Staley's Staclipse JUB) 0.4%, molasses (Del Monte's Brer Rabbit green 
label) 0.5%, Lexein F-152 liquid peptone (Inolex) 0.4%, soybean flour 0.5%, 
NZ amine type A (Sheffield) 0.1%, yeast extract (Difco) 0.1%, MgS0 4 
(anhydrous) 0.02%, CaC03 0.1%, and antifoam XFO-371 (Ivanhoe 
Chemical Co.) 0.01%. The fermentation was performed in a New Brunswick 
150-liter fermentor charged to a volume of 80 liters. Incubation was at 30 °C 
for 162 hours with an agitation rate of 200 rpm, an aeration rate of 0.7 w m 
and a head pressure of 0.35 kg/cm2. 
Inoculum for Fermentation 
Vegetative seed growth was frozen at -75 °C and used to inoculate the 
seed tubes of subsequent fermentations. The seed medium consisted of 
glucose monohydrate 0.1%, starch (Staley's Staclipse JUB) 2.4%, yeast 
extract (Difco) 0.1%, Tryptone (Difco) 0.5%, beef extract (Scott) 0.3%, and 
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CaCC-3 0.4%. The medium was prepared in distilled water and adjusted to 
pH 7 prior to sterilization. Ten mL of medium in 25 x 150 mm culture tubes, 
covered with Beilco stainless caps, were inoculated with 0.5 mL of frozen 
seed stock. The tubes were incubated for 96 hours. Two-liter Erlenmeyer 
flasks, containing 600 mL medium, were inoculated with the tube growth at 
5% and incubated for 72 hours. The second passage flask growth was used 
to inoculate the fermentation al 5%. Both seed steps were incubated at 30°C 
on a rotary shaker at 250 rpm (3.2 cm stroke). 
Labeled substrate (99% 1 3C-enriched) was added to the second 
passage seed on each of days 3, 4, and 5. The fermentation was harvested 
on day 6 and the pH adjusted to 4. 
Isolation of Labeled Coloradocin 
The labeled sample was extracted by passage over a column of XAD-2 
resin, which was rinsed well with water and stripped with methanol. The 
crude material was purified by reabsorption onto XAD-2 and eluted with a 
gradient of water to methanol. Coloradocin-containing fractions were 
combined and repurified on low pressure columns of C18 RP silica gel in 
CH 3 CN-H 2 0 (1:1) to obtain spectroscopically pure coloradocin. 
13C NMR Spectra 
NMRs were obtained on a Bruker AM-500 (500 MHz) spectrometer 
using a 5 mm probe. Samples were run in CD2CI2 in which solvent the C17 
and C19 carbon signals were poorly resolved. Signals were reported in 
parts per million (ppm) using the C D 2 C I 2 signal as reference peak. 
Enrichment for single labeled substrates were calculated by comparing peak 
heights of labeled samples relative to that of the same carbon from 
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unlabeled coloradocin spectrum measured under identical parameters. The 
relative peak heights for experiments with substrate other than methionine 
were normalized to the ratio of the C23 signals at 58.2 ppm. For double 
labeled substrates, the enrichment was presented as the ratio of the sum of 
the peak height of the satellites to the height of the center peak. 
119 
References 
1. Omura, S.; Iwata, R.; Iwai, Y.;Taga, S.;Tanaka, Y . ; Tomoda, H. J. 
Antibiotics 1985, 38, 1322. 
2. Jackson, M.; Karwowski, J . P.; Theriault, R. J . ; Fernandas, P. B.; 
Semon, R. C. ; Kohl, W. L J. Antibiotics 1987, 40,1375. 
3. Rasmussen, R. R.; Scherr, M. H.; Whittem, D. N.; Buko, A. M.; 
McAlpine, J . B. J . Antibiotics1987, 40, 1383. 
4. Celmer, W. D.; Chmurny, G. N.; Moppett, C. E.; Ware, R. S.; Watts, P. 
C. ; Whipple, E. B. J. Am. Chem. Soc. 1980, 102, 4203. 
5. Whaley, H. A.; Chidester, C. G.; Mizsak, S. A. ; Wnuk, R. J . 
Tetrahedron Lett. 1980, 21, 3659. 
6. Corcoran, J . W. In Antibiotics. VoilV. Biosynthesis, Corcoran, J . W„ 
Ed.; Springer: Berlin, 1981; pp 132-174. 
7. Omura, S . ; Nakagawa, A. In Antibiotics. Vol IV. Biosynthesis, 
Corcoran, J . W., Ed.; Springer: Berlin, 1981; pp 175-192. 
8. Cane, D. E. ; Yang, C.-C. J. Am. Chem. Soc. 1984, 106, 784. 
9. Snyder, W. C . ; Rinehart, K. L, Jr. J. Am. Chem. Soc. 1984, 106, 787. 
10. Holzbach, R.; Pape. H.; Hook, D.; Kreutzer, E. F.; Chang, C . - J . ; Floss, 
H. G. Biochemistry 1978, 17, 556. 
11. Ross, H. G.; Chang, C.-J.; Mascaretti, O . ; Shimada, K. Planta Med. 
1978, 34, 345. 
12. Mascaretti, O.; Chang. C . - J . ; Floss, H. G. J. Nat. Prod. 1979,42, 455. 
120 
13. Mallams, A. K.; Puar, M. S.; Rossman, R. R.; McPhail, A. T.; 
Macfarlane, R. D.; Stephens, R. L J. Chem. Soc., Perkin Trans. 1 
1983, 1497. 
14. Tamaoki, T . ; Tomita, F. Tetrahedron Lett. 1983, 36, 595. 
15. Lehninger, A. L. Principles of Biochemistry; Worth: New York, 
1982; Vol. p 443. 
16. Lehninger, A. L. Principles of Biochemistry; Worth: New York, 
1982; Vol. p 522. 
17. Zubay, G. Biochemistry; Macmillan Publishing Company: New York, 
1988; Vol. p 506. 
121 
Part III 
Total Synthesis of the Naturally Occurring 
Prenylated Bibenzyl Amorfrutin A 
A. Introduction 
Amorpha fruticosa is an indigenous American shrub used by 
Amerindians for bedding and as a mat for keeping freshly butchered meat 
clean. In a previous study, ethanolic extracts derived from the powdered 
fruits, stems, and leaves of Amorpha fruticosa showed reproducible 
antibacterial activity in vitro against Mycobacterium smegmatis (ATCC 607) 
and Staphylococcus aureus (ATCC 13709).1 Systematic bioassay-directed 
fractionation led to the isolation of the new rotenoid 11-hydroxytephrosin,2 
and two new bioactive carboxylated bibenzyl metabolites, amorfrutin A (1) 
and B(2). 3 
Two possible structures (1 and 3) for amorfrutins A and B were 
consistent with the spectral data (Figure 1). Although biogenetic 
considerations4 favored structure 1, unambiguous proof of the structure 
ultimately came from the synthesis of degradation product 4.2 This synthesis 
(Scheme 1) could have been modified for the production of the natural 
products themselves, however, the possibility of complications during the 
demethylation step, i.e. regioselective control of the cleavage and Lewis 
acid-catalyzed cyclization of the prenyl group with the newly formed hydroxyl 
group, would have reduced the unambiguity of the synthesis and made it 
more cumbersome. 
Because of the increasing number of bioactive carboxylated bibenzyls 
being reported in the literature,5'11 an efficient and flexible synthetic route to 
these compounds was desired in order to allow for convenient structure 
proof and to make them available in quantity for biological evaluation. 
122 
Structures of Amorfrutin A and B 
and of Degradation Product 4 
R 
R R 
Scheme 1 
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Curiously, no synthesis is yet available. One notes that, in addition to 
their antimicrobial properties, these compounds also show insect repellent 
properties 1 2 and are endogenous plant growth regulators. 1 2" 1 4 Some 
examples of carboxylated stilbenoids are shown in Figure 2. 
Because of the reasons mentioned above, our objective was the design 
of a flexible and unambiguous route to 2-carboxylated bibenzyls. The key 
intermediate 10 (Scheme 4), in principle, can also provide convenient 
access to analogously substituted 3,4-dihydroisocoumarin,15 isocoumarin,15 
and stilbene derivatives. The synthesis of these natural products is both 
important and desirable due to their interesting biological properties as 
antimicrobial agents (phytoalexins) and plant endogenous growth regulatory 
substances. 
B. Results and Discussion 
The synthesis of amorfrutin A presented two problems dealing with 
regiospecificity: the introduction of the carboxyl and the prenyl groups. The 
regiospecific introduction of the prenyl group was solved as a consequence 
of the solution found for installing the carboxyl group. The introduction of the 
carboxyl group was conceived as occurring via an intramolecular Friedel-
Crafts acylation of intermediate 7, and with the appropriate catalyst and 
reaction conditions, selective monodemethylation would also be 
accomplished during the process of the reaction (see retrosynthetic analysis, 
Scheme 2). Further manipulation of 8 would generate the carboxyl group at 
the 2 position. 
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2-Carboxylated Stilbenoids and their Sources 
from Cajanus cajan 11 from L cruciata, F.dilatata, from H.umbraculigerum 
C02H 
Ri : H R 2 : M e ^ ^ H C ^ 
:M62C-CHCH2 R 2 : H 
from Radula variabilis 8 
and F.tamarisci 
.OH 
10 
C02H 
Ar: 4-OH-Ph 
Lunularic Acid 
o 
from R. variabilis & 
R. complanata7 
and R complanata 
R 
H O V r O H 
v 
R: Me2C=CHCH2 
from R complanata7 
O 
OH 
CO2H 
from Helichrysum 
umbraculigerum9 
"COjH 
from Helichrysum 
umbraculigerum9 
COjH 
HO. 
from Helichrysum 
umbraculigerum9 
Figure 2 
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Retrosynthetic Analysis 
8 7 
Scheme 2 
The synthesis began with the Knoevenagel condensation of benzyl 
cyanide with 3,5-dimethoxybenzaldehyde under basic conditions to afford 
the stilbene derivative 5 in 94% yield. Occasionally, under the same 
apparent conditions, bisadduct 16 was obtained as the major product. 
Alkene reduction of 5 was performed with 5% Na(Hg) to afford the bibenzyl 
intermediate 6 in 99% yield. Acid hydrolysis of the cyano group gave 
carboxylic acid 7 (80%). As planned, intramolecular Friedel-Crafts acylation 
126 
and selective monodemethyiation were accomplished in the same step by 
the use of B C I 3 at -20 °C to produce the indanone derivative 8 in 97% yield 
(Scheme 3). 
a) SN NaOH/EtOH, 94%; b) 2.5% Na(Hg)/EtOH, 99% 
c) 2N NaOH/90% EtOH, 80%; d) BCI3, -20 °C/CH2CI2, 97% 
Scheme 3 
At this point, the regiospecific introduction of the carboxyl group was 
essentially solved and the appropriate hydroxyl group of amorfrutin A was 
freed to serve as a conductor for installation of the prenyl or geranyl units. At 
this stage, it was necessary to transform the cyclic ketone into a carboxylic 
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group through cleavage on the appropriate side. This transformation could 
have been performed by a Baeyer-Villager rearrangement of compound 8, 
but this process would have cleaved the cyclic ketone on the wrong side. 
Cleavage on the appropiate side was accomplished by reacting 8 with 
acetic anhydride and H2SO4 catalyst to give enol acetate 9 in 97% yield. 
Under the same conditions, the phenolic hydroxyl group was also 
acetylated. Ozonolysis of 9 afforded the desired keto-acid intermediate 10 in 
97% yield. For production of amorfrutin A, removal of the keto group was 
accomplished in quantitative yield via hydrogenolysis over Pd-C to afford 
carboxylic acid 11. For the introduction of the prenyl group, methyl ester 12 
was prepared with diazomethane in 95% yield from 11. Compound 12 was 
then reacted with 3-chloro-3-methylbut-l-yne and Ki under basic conditions 
( K 2 C O 3 ) to afford dimethylprop-2-ynyl ether 13 in 30% yield. Partial 
hydrogenation over BaSOVPd-C poisoned with quinoiine gave ether 14 
(91%), which was rearranged in N.N-dimethylaniline under reflux to give 
amorfrutin A methyl ester (15) in 82% yield. Basic hydrolysis afforded 
amorfrutin A in 75% yield (Scheme 4). 
Intermediate keto-acid 10 could, if desired, afford isocoumarin 17 by 
enol-iactonization, and 3,4-dihydroisocoumarin 18 by reduction followed by 
lactonization. Base-promoted elimination of 18 could produce stilbene 19 
(Scheme 5). 
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e) Ac20/cat. H 2 S0 4 , 97%; f) 03/MeOH-CH2CI2, 97%; g) Hg/Pd-C, 100%; 
h) CHgN^EtgO, 95%; i) 3-chloro-3-methylbut-1-yne, Kl, K 2 C0 3 , 30%; 
j) H2/BaSO4/10% Pd-C/quinoline, 91%; k) N.N-dimethylaniline/reflux, 82%; 
I) 0.1 A/NaOH/H20, 75%. 
Scheme 4 
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19 
Scheme 5 
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C. Conclusions 
The total synthesis of the plant antimicrobial agent amorfrutin A (1) was 
accomplished in 12 steps from known 3,5-dimethoxybenzaldehyde and 
benzyl cyanide in 11% overall yield. The synthetic route employed was 
efficient, apparently flexible, and regiospecific for 2-carboxyiated bibenzyls 
and related molecules. It should make this and related molecules 
conveniently available in reasonable quantity. 
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EXPERIMENTAL 
Melting points were determined on a Thomas-Hoover capillary melting 
point apparatus and are uncorrected. Infrared (IR) spectra were obtained on 
an IBM FTIR 32 or Perkin Elmer 1420 spectrophotometer. Proton nuclear 
magnetic resonance ( 1H NMR) spectra were recorded on a Varian FT-80 (80 
MHz) spectrometer in the indicated solvents using tetramethylsilane as 
internal reference, unless otherwise specified. All chemical shifts are 
expressed in parts per million (5). Electron impact mass spectra (EIMS), 
chemical ionization mass spectra (CIMS), and high resolution mass spectra 
(HRMS) were obtained on a Varian CH-5 or Ribermag R10-10 mass 
spectrometer by Dr. Charles Judson and Robert Drake. Microanalyses were 
performed by Dr. Tho I. Nguyen on a Hewlett-Packard Model 185 CHN 
analyzer at the University of Kansas. Ultraviolet (UV) spectra were recorded 
on a Hewlett-Packard Diode Array 8450A. Ozonolyzes were carried out on a 
Welsbach T-23 ozonator. Flash chromatography and medium pressure 
liquid chromatography (MPLC) were performed on Merck silica gel (230-400 
mesh), and gravity column chromatography on Merck silica gel (70-270 
mesh). 
Reagents and solvents were used as obtained without further 
purification, unless otherwise indicated. Bulk grade solvents: Et20, hexanes, 
acetone, and MeOH were distilled before use. Methylene chloride (CH2CI2) 
was distilled immediately before use from P2O5. MeOH and EtOH were 
distilled from Mg turnings. Benzene was distilled from powdered C a H 2 . 
Acetic anhydride was distilled from NaOAc. 
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All reactions involving moisture- or oxygen-sensitive materials were 
performed in flame- or oven-dried glassware under a positive pressure of 
argon. 
2-Phenyl-3,5-dimethoxycinnamonitrI le (5). 3,5-Dimethoxy 
benzaldehyde (5.0 g, 30.09 mmol), benzyl cyanide (5.5 g, 46.95 mmol) in 
ethanol (40 mL), and sodium hydroxide (0.3 mL, 6/V) were stirred at room 
temperature for 24 h. The precipitate obtained was filtered, washed with cold 
ethanol, and crystallized from CH2CI2 to give 5 (7.5g, 94%) as white 
crystals: mp 69-70 °C; UV (CH3CN), Xmax (e) 314 (2 215), 228 (16 410) nm; 
IR (neat) 3100, 2950. 2900, 2800, 2250 (CN), 1587, 1456, 1155, 837, 762 
cm" 1 ; 1 H NMR (CDCI3) 5 7.68-7.25 (m, 7H), 7.05 (d, J - 2 Hz, 1H), 6.54 (s, 
1H), 3.84 (s, 6H); EIMS mlz (relative intensity) 266 (M+ + 1, 19.8), 265 (M+, 
100), 250 (15), 234 (12.5), 219 (9.6), 190 (28.5), 151 (8), 76 (10.5), 191 
(11.6). 
Anal. Calcd for C 1 7 H 1 5 N O 2 : C, 76.98; H, 5.66; N, 5.28. Found: C, 76.80; 
H, 6.00; N, 5.28. 
1,3-Dicyano-1,3-diphenyl-2-(3,5-dimethoxyphenyl)propane 
(16). To a solution of 3,5-dimethoxybenzaldehyde (12.5 g, 75.4 mmol), 
benzyl cyanide (9.7 g, 82.9 mmol), and ethanol (100%, 30 mL) was added 
dropwise 6 N NaOH (0.2 mL, 1.2 mmol). The reaction mixture was stirred 
overnight at room temperature. A precipitate was seen after 30 minutes of 
stirring which was removed by filtration, washed with cold water-methanol 
solution (1:1, 3 x 25 mL), and then with cold water (3 x 25 mL). The resulting 
solid was recrystallized from CH2Cl2-hexanes (1:3) to yield 16 (17.04 g, 
59%) as a pure white solid: mp 203.5-204 °C; UV (CH3CN), Xmax (e) 204 (29 
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450), 231 (6 000, sh), 285 (2 260) nm; IR (KBr) 2961, 2938, 2250, 1587, 
1354, 1315, 1064, 837, 762, 690 cm'1; 1 H NMR (CDCI 3) 5 7.37 (s, 10H), 
6.40 (s, 1H), 6.24 (s, 2H), 4.1 (d, J = 8 Hz, 2H), 3.69 (s, 6H), 3.29 (t. J = 8 Hz, 
1H); EIMS mlz (relative intensity) 382 (M+), 265 (100), 250 (20), 190 (40). 
Anal. Calcd for C25H22N2O2: C, 78.51; H, 5.80; N, 7.33. Found: C, 
78.49; H, 5.81; N, 7.30. 
2 - P h e n y l - 3 - ( 3 , 5 - d i m e t h o x y p h e n y l ) p r o p i o n i t r i l e (6) . A 
suspension of 5 (4.5 g, 16.96 mmol) and 2.5% sodium amalgam (4.5 g) in 
anhydrous ethanol (50 mL) was kept at 60 °C for 2 h. The reaction was 
filtered and the solvent was removed under reduced pressure. The residue 
was redissolved in CH2CI2 (50 mL) and washed with dil. HCI (3 x 20 mL) 
and water (4 x 25 mL), dried (Na2S04), and concentrated under reduced 
pressure to give 6 (4.5 g, 99%) as a thick colorless oil: UV (CH3CN), Xmax (E) 
298 (17 850), 292 (17 850) nm; IR (neat) 3003, 2959, 2939, 2250, 1599, 
1464, 1153, 837, 756, 736 cm*l; 1H NMR (CDCI3) 8 7.22 (s, 5H), 6.62 (d. J 
=2 Hz, 1H), 6.18 (d, J - 2 Hz. 1H), 3.90 (t. J - 7 Hz, 1H), 3.63 (s, 6H), 3.0 (d, J 
= 7 Hz, 2H); EIMS, mlz (relative intensity) 268 (M+ + 1, 5.2), 267 (M+, 30.8), 
151 (100), 116 (5.4), 91 (11.6), 78 (22.4), 77 (36.7). 
Anal. Calcd for C17H17NO2: C, 76.38; H, 6.41; N, 5.24. Found: C, 76.10; 
H, 6.30; N, 4.90. 
2-Phenyl -3 - (3,5-dimethoxyphenyl )propanoic acid (7). A 
solution of 6 (4.0 g, 14.96 mmol) in 90% ethanol (50 mL) containing sodium 
hydroxide (4.0 g, 100.01 mmol) was refluxed for 24 h. The mixture was 
diluted with water (50 mL), concentrated to 40 mL, acidified with dil. HCI (2Af, 
60 mL), and extracted with ethyl acetate (3 x 25 mL). The organic layer was 
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washed with water (4 x 50 mL), dried (Na2S04), and concentrated under 
reduced pressure to afford 7 (3.43 g, 80%): mp 70-72 °C; UV (CH 3CN), Xm a x 
(E) 285 (1 850), 282 (1 830) nm; IR (neat) 3386 (br), 3165, 3088, 3063, 
3003, 2961, 1708, 1606, 1597, 1330, 1195, 1067, 835, 735. 698 CM - 1 ; 1H 
NMR ( C D C I 3 ) 8 10.48 (s, 1H), 7.28 (s, 5H), 6.24 (s, 2H), 3.65 (S, 6H), 3.62 (d, 
J = 7 Hz, 2H), 3.58 (q, J - 7 Hz, 1H); EIMS mlz (relative intensity) 287 (M+ + 
1, 5.7), 286 (M+, 27.3), 152 (15.9), 151 (100), 78 (8.0), 77 (17.0). 
Anal. Calcd for C17H18O4: C, 71.31; H, 6.34. Found: C, 71.20; H, 6.20. 
7-Hydroxy-5-methoxy-2-phenylindan-1-one (8). To a solution of 
7 (2.93 g, 10.23 mmol) in CH 2Cl2 (40 mL) at -20 °C, boron trichloride (5mL, 
1 M solution in CH2CI2) was added. After 3 h, the reaction was quenched by 
adding 95% ethanol (1.5 mL). The reaction mixture was reduced to about 
half the volume, washed with 5% sodium bicarbonate (3x10 mL) and water 
(3x10 mL). The solvent was removed and the residue was crystallized from 
ether to give 8 (2.53 g, 97%): mp 92-93 °C; UV (CH3CN), X m a x (e) 272 (21 
385), 221 (26 315) nm; IR (neat) 3333, 2950, 2850, 1668, 1630, 1599, 1495, 
1367, 1234, 1197, 1153, 841, 700, 677 cm-1; 1H NMR (CDCI3) 8 9.1 (br, s, 
1H), 7.24 (s, 5H), 6.49 (br, 1H), 6.32 (br, 1H), 3.86 (s, 3H), 3.75 (m, 1H), 3.25 
(m, 2H); EIMS mlz (relative intensity) 254 (M+, 100), 253 (M+ -1 , 21.5), 225 
(11.4), 211 (10.4), 177 (19.3), 165 (14.8), 152 (9.1), 127 (10.2), 91 (7.4). 
Anal. Calcd for C16H14O3: C, 75.57; H, 5.55. Found: C, 75.20; H, 5.50. 
5-Methoxy-1,7-diacetatoxy-2-phenylindene (9). To a cold (0 °C) 
solution of 8 (2.03 g, 7.56 mmol) in acetic anhydride (20 mL), cone. H2SO4 
(1 mL) was added and the reaction mixture was allowed to warm up to room 
temperature. After stirring for 12 h, the reaction mixture was poured over 
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3.85 (s, 3H), 2.20 (s, 3H); EIMS mlz (relative intensity) 328 (M+, 5.4), 311 
(57), 287 (19.4), 233 (12), 206 (5.4), 164 (30.1), 105 (100), 86 (20.4), 77 
(26.9). 
Anal. Calcd for C i 8 H 1 6 06: C, 65.85; H, 4.91. Found: C, 65.60; H, 5.10. 
3-Hydroxy-5-rnethoxybibenzyl -2-carboxyl ic acid (11). To a 
solution of 10 (1.5 g, 4.57 mmol) in 100% ethanol (70 mL), water (25 mL), 
and HCI (25 mL) was added 5% palladium charcoal (2.0 g) and the mixture 
was hydrogenated for 7 h at room temperature and 760 mm/Hg. The 
reaction mixture was filtered, concentrated to 50 mL, and diluted with cold 
water (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL) and 
the combined organic layer washed well with brine (3 x 25 mL), dried 
(Na2S04), filtered, and concentrated under reduced pressure. The solid 
obtained was crystallized from ethyl acetate-hexanes to afford 11 (1.19 g, 
100%): mp 128-131 °C (softens at 110 °C); UV (CH 3CN), X m a x (e) 302 (6 
770), 262 (15 960), 218 (36 220) nm; IR (KBr) 3433 (br), 3082, 2980, 2851, 
2685, 1799, 1628, 1616, 1581, 1473, 1367, 1261, 1205, 1122, 1005, 956 
cm-1; 1H NMR (CDCI3) 5 7.24 (s, 5H), 6.33 (s, 2H), 5.20 (br, 1H), 3.80 (s, 3H), 
3.25 (m, 2H), 2.80 (m, 2H); EIMS, mlz (relative intensity) 272 (M+, 47.7), 254 
(100), 239 (3.4), 225 (10.2), 181 (14.8), 135 (13.6), 91 (13.6). 
Anal. Calcd for C16H16O4: C, 70.57; H, 5.92. Found: C, 70.50; H, 5.80. 
3-Hydroxy-5-methoxy-2-carbomethoxybibenzyl (12). To a cold 
(5 °C) solution of 11 (1.0 g, 3.67 mmol) in ether (25 mL) was added excess 
of diazomethane in ether. After concentration, the residual solid which 
recrystallized from ether-hexanes to give 12 (1.0 g, 95%): mp 48.5-49.5 °C; 
UV ( C H 3 C N ) , Xmax (e) 302 (5 330), 262 (12 545), 218 (28 530) nm; IR (neat) 
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3084, 3026, 3003, 2953, 1724, 1653, 1616, 1496, 1435, 1381, 1259, 1159, 
1047, 956, 750 cm-1; ^H NMR (acetone-d6) 8 12.42 (s, 1H), 7.22 (br, 5H), 
6.37 (d, J = 2.5 Hz, 1H), 6.27 (d, J = 2.5 Hz, 1H), 3.95 (s, 3H), 3.80 (s, 3H), 
3.15 (m, 2H), 2.90 (m, 2H); EIMS mlz (relative intensity) 286 (M+, 17.6), 254 
(49.2), 195 (13.9), 165 (9.1). 135 (12.6), 91 (100). 
Anal. Calcd for C17H18O4: C, 71.31; H, 6.34. Found: C, 71.02; H, 6.30. 
3 - 0 - ( a , a -D Imethy lpropargy l ) -5 -methoxyb ibenzy l (13). A 
suspension of 12 (400 mg, 1.40 mmol), K2CO3 (900 mg, 6.51 mmol), Kl (1.2 
g, 7.23 mmol), and 3-chloro-3-methylbut-1-yne (160 mg, 1.56 mmol) in 
acetone (20 mL) was refluxed for 24 h. The reaction mixture was filtered and 
the residue washed with acetone (20 mL). The filtrate and washings were 
combined and the solvent removed under reduced pressure. The residue 
was purified by PCTLC (hexanes-ether 9:1) to obtain 13 as a colorless 
liquid (150 mg, 30%): UV (CH3CN), Xmax (e) 302 (5 850), 262 (13 735) nm; 
IR (neat) 3063, 3001, 2953, 2847, 1653, 1616, 1578, 1435, 1381, 1306, 
1215, 1159, 1047. 700 CM-1;1H NMR (CDCI 3)8 7.18 (m, 5H), 7.10 (d, J - 2 
Hz, 1H), 6.32 (d, Jm 2 Hz, 1H), 3.82 (s, 3H), 3.72 (s, 3H), 3.87 (s, 4H), 2.60 (S, 
1H), 1.64 (s, 6H); EIMS mlz (relative intensity) 352 (M+, 0.5) 321 (0.9), 286 
(2.8), 254 (19), 165 (6), 105 (2.6), 91 (100), 77 (16.1), 67 (23.5); EIHRMS 
calcd for C20H17O7: 352.16732; found: 352.16729. 
3 -0 - (a , a-Dimethy!allyl)-5-methoxybibenzyl (14). To a solution 
of 13 (100 mg, 0.28 mmol) in methanol (25 mL) was added BaSCVPd-C 
(10%) poisoned by quinoline (9 mg) and hydrogenated for 2 h at room 
temperature and 760 mm/Hg. The reaction mixture was filtered through 
celite and the residue washed with methanol ( 4 x 5 mL). The solvent was 
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evaporated and the residue was purified by PCTLC (hexanes-ether 3:1) to 
give 14 as a colorless liquid (91 mg, 91%): UV (CH 3 CN), Xmax (e) 229 
(1435), 283 (365, sh), 305 (130, sh) nm; IR (neat) 2982, 2932, 1728, 1601, 
1581, 1454, 1431, 1325, 1261, 1219, 1157, 1132, 1099, 1049 cm"1;lH NMR 
(CDCI3) 8 7.20 (s, 5H), 6.56 (d, J = 2 Hz, 1H), 6.28 (d, J = 2 Hz, 1H), 6.20 (m, 
1H), 3.84 (s, 3H), 3.66 (s, 3H), 2.84 (s, 4H), 1.44 (s, 6H); EIMS mlz (relative 
intensity) 354 (M+, 32), 337 (48), 322 (23). 307 (85), 279 (38), 267 (50), 238 
(29), 226 (100), 207 (18.4). 
Anal. Calcd for C22H26O4: C, 74.55; H, 7.39. Found: C, 74.40; H, 7.30. 
Amorfrutin A Methyl Ester (15). A solution of 14 (85 mg, 0.24 
mmol) in N,N-dimethylani!ine (3 mL) was refluxed for 2 h. The reaction 
mixture was cooled and ether was added (30 mL). The mixture was 
transfered to a separatory funnel and washed with 2N sulfuric acid (2x10 
mL) and brine ( 2 x 1 5 mL). The organic layer was dried (Na2S04) and the 
solvent removed. The residue was purified by PCTLC (hexanes-ether 5:1) to 
give 15 (70 mg, 82%) which was identical ( 1 H NMR, IR, MS) to a sample 
prepared from natural amorfrutin A. 
Amorfrutin A (1). A solution of 15 (37 mg, 0.11 mmol) and NaOH (40 
mg, 1.00 mmol) in 10 mL of water was refluxed for 4 h. The reaction mixture 
was cooled and acidified with dil. HCI and extracted with ethyl acetate (3 x 
10 mL). The combined organic layer was washed with water (2x10 mL) and 
brine (2x10 mL), dried (Na2SC-4), filtered, and concentrated under reduced 
pressure. The residue was crystallized from ether-hexanes to give pure 
amorfrutin A (27 mg, 75%): mp 145-146 °C, which was identical ( 1 H NMR, 
IR, MS) with an authentic sample. 
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